



# THOMSON REUTERS CONFERENCE POSTERS

## A Select List of Poster Presentations by Thomson Reuters Researchers

Since 1988, healthcare researchers at Thomson Reuters have conducted studies on disease progression, treatment patterns, health outcomes, and the associated costs to patients, employers, health plans, and the government. These studies have resulted in research published in peer-reviewed articles in leading journals, and numerous poster and podium presentations. Research conducted by Thomson Reuters has substantially contributed to the large body of highly respected research used to formulate policy decisions and improve healthcare for Americans.

This bibliography provides a listing of some of the most recent poster presentations. For a bibliography of published journal articles, go to <http://pharma.thomsonhealthcare.com> and click on the Bibliography link.

Authors in bold typeface are (or were at the time the work was written) Thomson Reuters staff.

## Anemia

---

Ellis L, Bailey R, Forlenza J, Senbetta M, **Blumberg P**. Inpatient transfusion practice and perisurgical outcomes in adult elective total hip replacement (THR) or total knee replacement (TKR) surgery patients <65 years of age.

*Clinical Conference of the American College of Nurse Practitioners*; October 5–9, 2011; Denver, CO.

Ellis L, Bailey R, Forlenza J, Senbetta M, **Blumberg P**. Patterns in preoperative anemia screening in elective total hip replacement or total knee replacement surgery.

*Society for the Advancement of Blood Management—2010 Annual Meeting*; September 24–26, 2010; San Juan, Puerto Rico.

*Clinical Conference of the American College of Nurse Practitioners*; October 5–9, 2011; Denver, CO.



Henry DH, Langer CJ, McKensie RS, Tak Piech C, Senbetta M, **Schulman KL**. Pre- and post-national coverage determination (NCD) hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA): Results from a multicenter chart review.

*51st American Society of Hematology Annual Meeting*; December 5–8, 2009; New Orleans, LA.

Lee A, **Song X**, Khan I, Belozeroff V, Goodman B, Fulcher N, **Diakun D**. The association between cinacalcet adherence and inpatient costs in chronic dialysis patients.

*National Kidney Foundation (NKF) 2011 Spring Clinical Meetings*; April 26–30, 2011; Las Vegas, NV.

Nassar G, Provenzano R, **Schulman K**, Law A, Wish J. Frequency of Hb testing and anemia diagnosis in patients with chronic kidney disease during the pre- and post-dialysis period.

*National Kidney Foundation 2007 Spring Clinical Meetings*; April 10–14, 2007; Orlando, FL.

Vogel S, del Aguila M, **Schulman K**, Wish J, Provenzano R. The effects of consistent erythropoiesis-stimulating agent (ESA) use prior to onset of dialysis on cardiovascular outcomes.

*American Nephrology Nurses Association's 38th National Symposium*; April 22–25, 2007; Dallas, TX.

Vogel S, Law A, **Schulman K**, Provenzano R, Nassar G. Frequency of Hb testing and anemia diagnosis in patients with chronic kidney disease during pre- and post-dialysis.

*American Nephrology Nurses Association's 38th National Symposium*; April 22–25, 2007; Dallas, TX.

Wish J, Amy W, **Schulman, KL**. Cost burden of anemia in a pre-dialysis cohort of patients with chronic kidney disease (CKD).

*AMCP 2006 Educational Conference Hyatt Regency*; October 4–7, 2006; Chicago, IL.

*Renal Week 2006, American Society of Nephrology*; November 14–19, 2006; San Diego, CA.

Wish J, Law AW, **Schulman KL**. Extended dosing with darbepoetin alfa in pre-dialysis chronic kidney disease (CKD) appears to be limited to patients with low dose requirements.

*National Kidney Foundation 2006 Spring Clinical Meetings*; April 19–23, 2006; Chicago, IL.

Wish J, Provenzano R, **Schulman K**, Law A, Nassar G. Frequency of Hb testing and anemia diagnosis in patients with chronic kidney disease during pre and post-dialysis period.

*National Kidney Foundation, 2007 Spring Clinical Meetings*; April 10–14, 2007; Orlando, FL.

Wish J, **Schulman K**, del Aguila M, Nassar G, Provenzano R. The effects of consistent erythropoiesis-stimulating agent (ESA) use prior to onset of dialysis on cardiovascular outcomes: A retrospective claims database analysis

*27<sup>th</sup> Annual Conference on Dialysis*; February 18–20, 2007; Denver, CO.

Wish J, **Schulman, K**, Law A. A retrospective claims analysis of anemia treatment patterns in patients with chronic kidney disease with and without diabetes.

*Renal Week 2006, American Society of Nephrology*; November 14–19, 2006; San Diego, CA.



Wish J, **Schulman KL**, Law AW. Extended intervals using epoetin alfa in pre-dialysis patients with chronic kidney disease (CKD) appears to be limited to patients with low dose requirements.

*National Kidney Foundation 2006 Spring Clinical Meetings; April 19–23, 2006; Chicago, IL.*

Wish J, **Schulman K**, Law A. Medication burden in patients with chronic kidney disease and anemia treated with and without erythropoiesis-stimulating agents.

*Renal Week 2006, American Society of Nephrology; November 14–19, 2006; San Diego, CA.*

## Autoimmune Diseases

---

**Bonafede M**, Gandra SR, Watson C, **Princic N**, Fox KM. Cost of etanercept, adalimumab, and infliximab per treated patient across adult indications using real world data. **(Best Poster Finalist)**

*ISPOR 14th Annual European Congress; November 5–8, 2011; Madrid, Spain.*

**Bonafede M**, **Johnson BH**, Fox KM, Watson C, Gandra SR. A retrospective analysis of risk factors for non-initiation of a DMARD among a cohort of newly diagnosed RA patients.

*Annual European Congress of Rheumatology EULAR 2011; May 25–28, 2011; London, England.*

**Bonafede M**, **Johnson BH**, Fox KM, Watson C, Gandra SR. Risk factors for non-initiation of disease modifying anti-rheumatic drugs (DMARD) by patients with newly diagnosed rheumatoid arthritis (RA).

*ISPOR 16th Annual International Meeting; May 21–25, 2011; Baltimore, MD.*

**Bonafede M**, Watson C, Fox KM, **Princic N**, Gandra S. Tumor necrosis factor blocker treatment patterns after discontinuation within the first year of therapy initiation in rheumatoid arthritis patients in a real-world managed care setting.

*ACR/ARHP Annual Scientific Meeting; November 4–9, 2011; Chicago, IL.*

**Bonafede M**, Watson C, Fox KM, **Wilson KL**, Gandra S. Anti-tumor necrosis factor dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed care plans in the two years following therapy initiation.

*ACR/ARHP Annual Scientific Meeting; November 4–9, 2011; Chicago, IL.*

**Foley K**, Martin S, **Baser O**. Incremental medical costs associated with increased changes in HAART regimens.

*4th Annual International AIDS Society (IAS) Conference; July 22–25, 2007; Sydney, Australia.*

John A, Woodworth T, Stevens R, **Schulman K**, Sacks S. Upper and lower gastrointestinal perforations among RA patients treated with methotrexate alone or in combination.

*71st Annual Meeting, American College of Rheumatology; 42nd Annual Meeting, Association of Rheumatology Health Professionals; November 6–11, 2007; Boston, MA.*

**Johnston SS**, Juday T, Esker S, **Espindle D**, **Chu B**, Hebden T, Uy J. Comparative tolerability of protease-inhibitor-based combination antiretroviral therapy regimens in U.S. Medicaid HIV patients.

*13th European AIDS Conference/EACS; October 12–15, 2011; Belgrade, Serbia.*



**Johnston SS**, Juday T, Seekins D, **Espindle D**, **Chu BC**. Impact of prescription cost-sharing on adherence to HIV antiretroviral therapy.

*AMCP Annual Meeting; April 27–30, 2011; Minneapolis, MN.*

**Johnston SS**, Ogale S, **Princic N**, **Chu BC**, Kamath T. Switching patterns for biologic drugs among patients with rheumatoid arthritis who have previously failed at least one biologic agent.

*2010 ACR/ARHP Annual Scientific Meeting; November 6–11, 2010; Atlanta, GA.*

**Johnston S**, Turpcu A, **Shi N**, Moawad D, Alexander K. Incidence and hazard of infections in rheumatoid arthritis patients treated with subsequent-line biologic disease modifying antirheumatic drugs after switching from first-line anti-tumor necrosis factor agents.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting; August 14–17, 2011; Chicago, IL.*

**Johnston S**, Turpcu A, **Shi N**, Moawad D, Alexander K. Risk of cardiovascular events in rheumatoid arthritis patients treated with subsequent-line biologic disease modifying antirheumatic drugs after switching from first-line anti-tumor necrosis factor agents.

*ACR/ARHP Annual Scientific Meeting; November 4–9, 2011; Chicago, IL.*

Li T, **Wang S**, **Goetzel R**, Maclean R, **Ozminkowski R**. An assessment of medical costs associated with systemic lupus erythematosus and lupus nephritis.

*71st Annual Meeting, American College of Rheumatology; 42nd Annual Meeting, Association of Rheumatology Health Professionals; November 6–11, 2007; Boston, MA.*

**Margolis J**, Eynullayeva E, **Cao Z**, Baran RW, Dietz B. Comparative effectiveness of antiretroviral therapy in treatment-naïve patients infected with human immunodeficiency virus: A retrospective claims analysis of lopinavir/ritonavir, efavirenz, and atazanavir.

*13th European AIDS Conference/EACS; October 12–15, 2011; Belgrade, Serbia.*

Mueller CS, Wade S, **Song X**, Bolge SC, McKenzie S. Baseline characterization of adult patients with rheumatoid arthritis naïve to biologic therapy.

*ACMP Educational Meeting; October 13–16, 2010; St. Louis, MO.*

Ng E, **Gibson TB**, **Ozminkowski RJ**, **Goetzel RZ**, Burton W, **Wang S**, MacLean R. The direct and indirect cost burden of Crohn's disease.

*The American College of Gastroenterology 2007 Annual Scientific Meeting and Postgraduate Course; October 12–17, 2007; Philadelphia, PA.*

Ng E, **Gibson TB**, **Ozminkowski RJ**, MacLean R, Burton W, **Wang S**, **Goetzel RZ**. The direct and indirect cost burden of ulcerative colitis.

*The American College of Gastroenterology 2007 Annual Scientific Meeting and Postgraduate Course; October 12–17, 2007; Philadelphia, PA.*



**Ozminkowski R**, Li T, **Wang S**, **Goetzel R**, Maclean R, Panopolis P. The direct medical expenditures and costs to employers of systemic lupus erythematosus in comparison to other high cost and high prevalence conditions.

*71st Annual Meeting, American College of Rheumatology; 42nd Annual Meeting, Association of Rheumatology Health Professionals; November 6–11, 2007; Boston, MA.*

**Song X**, Kan HJ, **Johnson BH**, Bechtel B, O'Sullivan D, Molta C. Healthcare utilization of patients with systemic lupus erythematosus in a U.S. Medicaid population.

*ACR/ARHP Annual Scientific Meeting; November 4–9, 2011; Chicago, IL.*

Yazici Y, **Shi N**, John A. Sequencing of drug therapy in a cohort of newly diagnosed rheumatoid arthritis (RA) patients in the U.S.: An analysis of 16,752 RA patients, 1998–2006.

*71st Annual Meeting, American College of Rheumatology; 42nd Annual Meeting, Association of Rheumatology Health Professionals; November 6–11, 2007; Boston, MA.*

## Cardiovascular

---

Amin AN, **Lenhart G**, Lin J, Thompson S, **Johnston S**. Duration of risk of venous thromboembolism in real-world US surgical patients.

*11th National Conference on Anticoagulant Therapy; May 5–7, 2011; Boston, MA.*

Amin AN, Lin J, **Johnson BH**, **Schulman KL**. Clinical outcomes in patients at risk of venous thromboembolism receiving appropriate or partial prophylaxis.

*American Thoracic Society 2009 International Conference; May 15–20, 2009; San Diego, CA.*

Amin A, Lin J, **Lenhart G**, **Schulman K**. Clinical outcomes in patients at risk for venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.

*Society of Hospital Medicine's Annual Meeting; May 14–17, 2009; Chicago, IL.*

Amin AN, Lin J, **Lenhart G**, **Schulman KL**. Economic outcomes in patients at risk for venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.

*American College of Allergy, Asthma, and Immunology Annual Meeting; November 6–8, 2008; Seattle, WA.*

Amin AN, **Princic NP**, Lin J, Thompson S, **Johnston SS**. Real-world analysis of the duration of risk of venous thromboembolism in US surgical patients.

*52nd ASH Annual Meeting and Exposition; December 4–7, 2010; Orlando, FL.*

Amin A, **Varker H**, Lin J, Thompson S, **Johnston S**. Duration of risk of venous thromboembolism in real-world US patients hospitalized for medical illness

*Society of Hospital Medicine's Annual Meeting; May 10–13, 2011; Dallas, TX.*

Amin A, **Varker H**, Lin J, Thompson S, **Johnston S**. Duration of the risk of VTE in US medical patients.

*Society of General Medicine Annual Meeting; May 4–7, 2011; Phoenix, AZ.*



**Bonafede M**, Jing Y, Gdovin Bergeson J, **Liffmann DK**, Makenbaeva D, Graham JP, Deitelzweig S. Potential economic impact of dyspnea associated with ticagrelor use.

*ISPOR 16th Annual International Meeting; May 21–25, 2011; Baltimore, MD.*

**Bonafede M**, Shorr A, **Johnson B**, Horblyuk R. Fondaparinux is economically non-inferior to enoxaparin for the treatment of venous thromboembolism.

*ISPOR 14th Annual International Meeting; May 16–20, 2009; Orlando, FL.*

**Chang S**, **Huse D**, **Hansen L**. Measuring the effect of an inpatient stay on adherence to medications: Clopidogrel bisulfate use post-discharge.

*PMSA Annual Conference; April 26–30, 2008; Las Vegas, NV.*

**Curkendall S**, Mozaffari E, **Johnston S**, **Goetzel R**, Burton W, Maclean R. The economic burden of acute coronary syndrome to employers.

*9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; April 23–25, 2009; Washington, DC.*

Deitelzweig S, Lin J, **Johnson B**, **Schulman K**. Prevalence of venous thromboembolism across ethnic groups in the United States.

*51st American Society of Hematology Annual Meeting; December 5–8, 2009; New Orleans, LA.*

Deitelzweig S, Lin J, **Johnson B**, **Schulman K**. Prevalence of venous thromboembolism in the USA: Now and the future.

*National Conference on Blood Disorders in Public Health; March 9–11, 2010; Atlanta, GA.*

Deitelzweig SB, Lin J, **Johnson BH**, **Schulman, KL**. Trends in the prevalence of venous thromboembolism in the United States.

*21st International Thrombosis Conference; July 6–9, 2010; Milan, Italy. (Best Poster Winner)*

Gheorghide M, **Margolis J**, Pan K, Roberts C, Gordon P, Gerber RA. Aldosterone blocking agents usage in patients with heart failure.

*European Society of Cardiology, Congress 2009; August 29–September 2, 2009; Barcelona, Spain.*

**Gibson TB**, **Mark T**, Axelsen K. The effects of statin copayments and statin adherence on medical care utilization and expenditures.

*ISPOR 11<sup>th</sup> Annual International Meeting; May 20–24, 2006; Philadelphia, PA.*

**Gibson TB**, **Mark TL**, McGuigan K, Axelsen KA, **Wang S**, Mackell J. The effects of prescription drug copayments on statin adherence and persistence.

*American College of Clinical Pharmacy 2005 Spring Practice and Research Forum; April 10–13, 2006; Myrtle Beach, SC.*

**Hansen L**, **Foley K**. The relationship between patient beliefs and adherence to cholesterol-lowering medications: Implications for disease management programs.

*ISPOR 9<sup>th</sup> Annual European Congress; October 28–31, 2006; Copenhagen, Denmark.*



**Huse D, Lenhart G**, Rublee D. Does administratively-induced substitution of simvastatin for atorvastatin result in therapeutically equivalent dosages in Medicaid programs?

*9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke*; April 30–May 2, 2008; Baltimore, MD.

**Johnston SS**, Bell K, Gdovin Bergeson J, **McMorrow D**, Graham J. Patterns of acute clopidogrel use and inpatient costs in acute coronary syndrome patients undergoing coronary artery bypass grafting.

*ISPOR 16th Annual International Meeting*; May 21–25, 2011; Baltimore, MD.

Kim MH, **Chu B**, Lin J, **Schulman K**. Total healthcare costs among atrial fibrillation patients in the United States in 2010.

*ACC 10: American College of Cardiology 59th Annual Scientific Session*; March 14–16, 2010; Atlanta, GA.

Kim MH, **Johnston S**, Lin J, **Schulman K**. Estimation of incremental cardiovascular healthcare costs in patients with atrial fibrillation in the United States.

*ACC 10: American College of Cardiology 59th Annual Scientific Session*; March 14–16, 2010; Atlanta, GA.

**Margolis J**, McMorrow D, **Johnson B**, Hvidsten K, Watt S, Benza R, Murali S. Hospitalizations of pulmonary arterial hypertension patients stabilized on oral sildenafil.

*9th International Pulmonary Hypertension Conference & Scientific Sessions*; June 25–27, 2010; Garden Grove, CA.

**Misra A, Hansen LG, Chang S**. Periodontal disease, statin use, and cardiovascular events.

*ISPOR 12th Annual European Congress*; October 24–27, 2009; Paris, France.

**Mucha L**. Switching, augmentation and titration of lipid lowering agents of Medicare Medicaid dual eligible patients by ethnicity.

*134th American Public Health Association Annual Meeting & Exposition*; November 4–6, 2006; Boston, MA.

**Mucha LM, Mark T**, Axelsen K. Switching, augmentation and titration of lipid lowering agents of Medicare/Medicaid dual eligible patients by ethnicity.

*AcademyHealth Annual Research Meeting*; June 25–27, 2006; Washington, DC.

*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.

Naccarelli GV, **Johnston SS**, Dalal M, Lin J, Patel PP, **Schulman KL**. Hospitalizations and inpatient mortality over one year in patients with atrial fibrillation/atrial flutter and without heart failure in the United States: Does age matter?

*American Heart Association 2010 Meeting*; November 13–17, 2010; Chicago, IL.

Naccarelli GV, **Johnston SS**, Dalal M, Patel PP, **Schulman KL**. Hospitalizations and inpatient mortality over one year in patients with atrial fibrillation/atrial flutter and without heart failure in the United States: Does age matter?

*Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2010 Scientific Sessions*; May 19–21, 2010; Washington, DC.



Naccarelli GV, **Johnston SS**, Lin J, Patel PP, **Schulman KL**. Cost burden of ATHENA endpoints in United States atrial fibrillation/atrial flutter patients.

*Heart Rhythm 2009*; May 13–15, 2009; Boston, MA.

Naccarelli G, **Varker H**, Lin J, **Schulman K**. Effect of ethnicity on prevalence of atrial fibrillation among Medicaid patients.

*Heart Rhythm 2010*; May 12–15; 2010; Denver, CO.

Naccarelli GV, **Varker H**, Lin J, **Schulman KL**. Increasing prevalence of atrial fibrillation and flutter in the United States: Is it just due to the population aging?

*American College of Cardiology 58th Annual Scientific Session*; March 29–31, 2009; Orlando, FL.

Patel P, Gregory C, Lin J, **Schulman K**, H Naccarelli G. Hospitalization and mortality in patients with atrial fibrillation/atrial flutter and among ATHENA-like patients in the United States.

*9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke*; April 23–25, 2009; Washington, DC.

Patel PP, **Johnston SS**, Lin J, Schulman **KL**, Naccarelli GV. Cost burden of hospitalization and mortality in United States atrial fibrillation/flutter patients.

*Heart Rhythm 2009*; May 13–15, 2009; Boston, MA.

Patel PP, **Johnston SS**, Lin J, **Schulman KL**, Naccarelli GV. Hospitalization and mortality in advanced-age patients with atrial fibrillation/atrial flutter but without heart failure in the United States.

*ISPOR 12th Annual European Congress*; October 24–27, 2009; Paris, France.

Patel PP, Naccarelli GV, **Johnston SS**, Lin J, **Schulman KL**. Cost burden of Athena endpoints in Athena-like patients with atrial fibrillation/atrial flutter but without heart failure in the United States.

*ISPOR 12th Annual European Congress*; October 24–27, 2009; Paris, France.

**Schulman K**, **Johnston SS**, Lin J, **Huse DM**. Prevalence of atrial fibrillation (AF) in the US.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting*; August 19–22, 2010; Brighton, UK.

Shorr A, **Bonafede M**, **Johnson B**, Horblyuk R. Economic outcomes for venous thromboembolism management based on anticoagulation choice.

*CHEST 2009, American College of Chest Physicians*; October 31–November 5, 2009; San Diego, CA.

**Short ME**, **Goetzel RZ**, **Young JS**, **Kowlessar NM**, Liss-Levinson RC, **Tabrizi MJ**, Roemer EC, Sabatelli AA, Winick K, Montes M, Crighton KA. Measuring changes in lipid and blood glucose values in Prudential's health and wellness program.

*AcademyHealth Annual Research Meeting*; June 27–29, 2010; Boston, MA.

**Song X**. An assessment of costs in total hip or knee arthroplasty patients that experience venous thromboembolism during and post hospitalization.

*AMCP 21st Annual Meeting & Showcase*; April 15–18, 2009; Orlando, FL.



**Song X, Huse D, Sander S, Amin A.** Impact of atrial fibrillation and the use of oral anticoagulation on length of stay, hospital costs, and reimbursement.

*American Society of Health-System Pharmacists (ASHP) Summer Meeting; June 14–17, 2009, Village of Rosemont, IL.*

**Song X, Sander S, Huse D, Harris K, Amin A.** Anticoagulant prophylaxis use and rates of venous thromboembolism in patients with total hip or knee arthroplasty during and following hospitalization.

*9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; April 30–May 2, 2008; Baltimore, MD.*

**Song X, Sander S, Huse D, Harris K, Amin AN.** An assessment of hospital costs and reimbursement among total hip or knee arthroplasty patients in the United States that experience venous thromboembolism.

*ISPOR 13th Annual International Meeting; May 3–7, 2008; Toronto, Canada.*

**Song X, Sander S, Johnson B, Varker H, Amin A.** Incremental impact of oral anticoagulation among atrial fibrillation patients hospitalized on length of stay and cost to health plans.

*AMCP Educational Symposium; Oct 7–10, 2009; San Antonio, TX.*

**Song X, Sander S, Varker H, Amin A.** Patterns and predictors of persistence of warfarin and other commonly-utilized chronic medications among patients with atrial fibrillation.

*ISPOR 15th Annual International Meeting; May 15–19, 2010; Atlanta, GA.*

**Tomic KS, Sander SD, Siu K, Johnson BH, Amin A.** Hospital utilization, costs, and 30-day readmission rates among patients with non-valvular atrial fibrillation compared to non-atrial fibrillation patients.

*ASHP 2011 Summer Meeting; June 12–15, 2011; Denver, CO.*

**Tomic K, Sander S, Siu K, Smith DM, Amin A, Johnson BH.** Anticoagulant use, the prevalence of bridging and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation.

*ISPOR 16th Annual International Meeting; May 21–25, 2011; Baltimore, MD.*

## Depression

---

**Aeder H, Montejano L, Sasané R, Hodgkins P, Huse D.** Burden of illness and comorbidities in adult patients with attention-deficit hyperactivity disorder compared to patients with depression.

*American Psychiatric Association Annual Meeting; May 16–21, 2009; San Francisco, CA.*

**Bron MS, Mark TL.** The effect of raising three tier copayments on SSRI compliance rates.

*ISPOR 10<sup>th</sup> Annual International Meeting; May 15–18, 2005; Washington, DC.*

**Bron MS, Mark TL, Orsini LS.** Cost and utilization differences among cardiac patients treated for depression with sertraline versus no pharmaceutical treatment.

*ISPOR 10<sup>th</sup> Annual International Meeting; May 15–18, 2005; Washington, DC.*



**Curkendall S**, Joish V, Ruiz K, **Mark T**. Productivity losses occur due to depression even when patients are treated with antidepressants.

*2009 U.S. Psychiatric & Mental Health Congress; November 2–5, 2009; Las Vegas, NV.*

**Curkendall S**, Ruiz K, Seal B, **Mark T**. A high proportion of patients with severe depression use short-term disability leave.

*2009 U.S. Psychiatric & Mental Health Congress; November 2–5, 2009; Las Vegas, NV.*

**Durden E**, Happich M, **Shi N**, **Torres A**. Characteristics of patients with depression in the UK initiating treatment with duloxetine and venlafaxine.

*The 18th EPA European Congress of Psychiatry; February 27–March 2, 2010; Munich, Germany.*

**Gibson TB**, Jing Y, **Carls GS**, Kim E, **Bagalman JE**, Burton WN, Tran QV, Pikalov A, Goetzel RZ. The cost burden of treatment resistance in patients with depression.

*ISPOR 14th Annual International Meeting; May 16–20, 2009; Orlando, FL. (Best Poster Finalist)*

Jing Y, **Bagalman JE**, **Carls GS**, **Gibson TB**, **Durden E**, Hebden T, Bates J, Forbes R, Burton W, **Goetzel RZ**, Thase M. Regimen-based cost analysis of patients with depression who received augmentation therapy.

*U.S. Psychiatric and Mental Health Congress; November 18–21, 2010; Orlando, FL.*

Jing Y, **Bagalman JE**, **Carls GS**, **Gibson TB**, **Durden E**, Hebden T, Bates J, Forbes R, Burton W, **Goetzel RZ**, Thase M. Healthcare service use and costs of patients augmenting antidepressant treatment with second-generation antipsychotics.

*U.S. Psychiatric and Mental Health Congress; November 18–21, 2010; Orlando, FL.*

**Long S**, Robinson R, **Chang S**. Variations in depression treatment quality: Medicaid versus commercial claims.

*AcademyHealth Annual Research Meeting; June 26–28, 2005; Boston, MA.*

**Long S**, Robinson R, **Chang S**, Able S, **Baser O**, Swindle R. Appropriateness and variation in drug utilization across patients with depression.

*ISPOR 10<sup>th</sup> Annual International Meeting; May 15–18, 2005; Washington, DC.*

**Mark T**. An examination of psychiatric patients treated in general hospitals specialty units and scatter beds.

*AcademyHealth Annual Research Meeting; June 8–10, 2008; Washington, DC.*

**Mark T**. Evaluation of antidepressant step-therapy: Looking beyond prescription drug savings.

*14th NIMH Biennial Research Conference on the Economics of Mental Health: Toward Building a High Performance Mental Health System; September 25–26, 2008; Bethesda, MD.*

**Shi N**, **Durden E**, **Cao Z**, **Torres A**, Happich M. Healthcare utilization of patients with depression before and after initiating duloxetine.

*ISPOR 13<sup>th</sup> Annual European Congress; November 6–9, 2010; Prague, Czech Republic.*



Whiteley J, **Landsman-Blumberg PB**, **Cao Z**, Alvir J, Harnett J. Effects of a desvenlafaxine prior authorization on healthcare resource utilization and costs in commercially insured patients.

*AMCP Educational Meeting*; October 19–21, 2011; Atlanta, GA.

## Diabetes and Metabolic

---

**Chang S, Hansen L, Marder W**. A methodology for projecting diabetes prevalence and treatment rates for the U.S. employer-insured population.

*23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*; August 19–22, 2007; Quebec City, Canada.

**Curkendall S, Oh K**, Pollack M, Williams S, Krishnarajah G, Balar B, **Ruiz K**. Frequency of diagnosed hypoglycemia among patients with type 2 diabetes.

*ACMP Educational Meeting*; October 13–16, 2010; St. Louis, MO.

**Curkendall S**, Zhang B, **Oh K**, Williams S, Pollack M, Graham JP. Direct medical cost of hypoglycemia among patients with type-2 diabetes in the United States.

*ISPOR 16th Annual International Meeting*; May 21–25, 2011; Baltimore, MD.

**Durden E**, Alemayehu B, **Chu B**, Forma F. The direct medical costs of patients with type 2 diabetes in employed populations, 2000 and 2005.

*AcademyHealth Annual Research Meeting*; June 8–10, 2008; Washington, DC.

**Durden ED**, Alemayehu B, Forma F. Lost productivity associated with type 1 and type 2 diabetes in a commercially insured population.

*ISPOR 13th Annual International Meeting*; May 3–7, 2008; Toronto, Canada.

**Durden E**, Ben-Joseph R, **Huse D, Chu BC**. The direct and indirect costs of obesity in an employed population.

*ISPOR 13th Annual International Meeting*; May 3–7, 2008; Toronto, Canada.

**Durden E, Bizier R, Huse D**. Influence of hemoglobin A1c test result on decision to initiate insulin supplementation in type 2 diabetes.

*ISPOR 12th Annual International Meeting*; May 19–23, 2007; Arlington, VA.

**Durden E**, Sarpong E. Unmet treatment needs among patients with type 2 diabetes uncontrolled on basal-only insulin therapy: Implications of adding bolus insulin therapy.

*44th EASD Annual Meeting*; September 7–11, 2008; Rome, Italy.

**Foley KA, Long SR**, Oglesby AK, Rousculp MD. Diabetic retinopathy claims in a commercially insured Medicare population.

*AMCP 2006 Educational Conference Hyatt Regency*; October 4–7, 2006; Chicago, IL.



**Gibson TB**, Driver VR, Wrobel J, Christina JR, **Bagalman E**, DeFrancis R, Garoufalls M, **Carls GS**, **Wang SS**. Podiatrist care and outcomes for patients with diabetes and foot ulcer.

*American Diabetes Association's 70th Scientific Sessions*; June 25–29, 2010; Orlando, FL.

**Gibson TB**, **Song X**, Alemayehu B, **Wang S**, Mell A, Forma F. Determinants of insulin initiation for patients with type 2 diabetes.

*ISPOR 13th Annual International Meeting*; May 3–7, 2008; Toronto, Canada.

**Gibson TB**, **Song X**, **Wang S**, Mell AG, Forma F, Alemayehu B. The effects of patient cost-sharing and adherence to antidiabetic medications on expenditures, utilization and complications.

*AcademyHealth Annual Research Meeting*; June 8–10, 2008; Washington, DC.

**Gibson TB**, **Wang S**, Alemayehu B, **Song X**, Mell AG, Forma F. Insulin initiation for commercially insured adults with type 2 diabetes.

*American Diabetes Association 68th Scientific Sessions*; June 6–10, 2008; San Francisco, CA.

**Huse D**, **Bizier R**. Impact of FDA safety warnings on subsequent diabetes care for users of rosiglitazone.

*ISPOR 12th Annual European Congress*; October 24–27, 2009; Paris, France.

**Johnston S**, Conner C, Aagren M, **Smith DM**, Bouchard J. Hypoglycemic events may be associated with an increased risk of acute cardiovascular events in patients with type 2 diabetes.

*American Diabetes Association's 70th Scientific Sessions*; June 25–29, 2010; Orlando, FL.

Kalsekar A, **Bonafede M**, Pawaskar M, McGuffie K, **Torres A**, Kelly KR, **Curkendall S**. A retrospective database analysis of persistence with insulin in patients with type 2 diabetes adding mealtime insulin to a basal regimen.

*ISPOR 12th Annual European Congress*; October 24–27, 2009; Paris, France.

**Margolis JM**, **Chu BC**, **Johnson BH**, Forma F, Alemayehu B. Differences in healthcare utilization and expenditures among Medicare patients with type 2 diabetes initiating analog & human insulins.

*AcademyHealth Annual Research Meeting*; June 8–10, 2008; Washington, DC.

**Margolis J**, **Johnson BH**, **Chu BC**, Forma F, Alemayehu B. Comparison of healthcare utilization and costs in type 2 diabetes patients initiating analog and human insulins.

*ISPOR 13th Annual International Meeting*; May 3–7, 2008; Toronto, Canada.

**Misra A**, **Hansen L**, **Chang S**. Drug-drug interactions among elderly patients with diabetes.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting*; August 16–19, 2009; Providence, RI.

**Orsini LS**, **Huse D**. Total healthcare costs in Medicaid patients receiving NPH, lente, or insulin glargine.

*American Diabetes Association 65<sup>th</sup> Annual Scientific Sessions*; June 10–14, 2005; San Diego, CA.

**Orsini LS**, Rhoads G, **Wang S**, Zhang Q, **Crown WH**. Increased health expenditures among diabetes patients on insulin with hypoglycemia.

*ISPOR 9<sup>th</sup> Annual International Meeting*; May 16–19, 2004; Arlington, VA.



**Palmer L, Baser O**, Arondekar B, Horblyuk R. Triple therapy with rosiglitazone or insulin and associated medical resource use and costs in type 2 diabetes.

*67th Scientific Session of the American Diabetes Association*; June 22–26, 2007; Chicago, IL.

**Palmer L**, Conner C, Hammer M, Bouchard JR, Anderson JA. Diabetes regimen utilization in a large managed care setting: A comparison with ADA/EASD consensus statement guidelines.

*ISPOR 12th Annual European Congress*; October 24–27, 2009; Paris, France.

Pawaskar M, **Bonafede M, Johnson BH, Fowler R**, Hoogwerf BJ. The impact of treatment modification on healthcare expenditure in patients with type-2 diabetes initiating exenatide bid or insulin glargine.

*ISPOR 16th Annual International Meeting*; May 21–25, 2011; Baltimore, MD.

Pawaskar M, **Bonafede M, Johnson BH, Fowler R**, Hoogwerf B. Time to treatment modification among patients with type 2 diabetes who initiated exenatide or insulin glargine.

*ISPOR 13<sup>th</sup> Annual European Congress*; November 6–9, 2010; Prague, Czech Republic.

Pawaskar M, **Bonafede M, Johnson BH, Fowler R**, Hoogwerf B. Time to treatment modification among patients with type 2 diabetes who initiated exenatide twice-daily or insulin glargine.

*Diabetes UK Annual Professional Conference 2011*; March 30–April 1, 2011; London England.

Rhoads GG, **Crown W, Orsini LM, Wang S**, Getahun D, Zhang Q. Short-term disability and medical care utilization associated with hypoglycemia.

*American Diabetes Association 64<sup>th</sup> Annual Scientific Sessions*; June 4–8, 2004; Orlando, FL.

Sarpong ED, **Durden ED**. The need for earlier insulin initiation and intensification among patients with type 2 diabetes: Evidence from health claims and laboratory database.

*ISPOR 13th Annual International Meeting*; May 3–7, 2008; Toronto, Canada.

**Song X**, Andrews LM, Francis BH, **Princic N**, Sedgley R, Agashivala N, Rudolph A. Healthcare utilization and costs among pre-diabetic patients who progress to type 2 diabetes mellitus.

*American Diabetes Association's 70th Scientific Sessions*; June 25–29, 2010; Orlando, FL.

## Drug Spending

---

**Foley K**, Corea J, Roberto P, Bryant J, **Marder W**. Improvements in economic well-being and access to prescription medications for the previously uninsured under the Medicare prescription drug program.

*AcademyHealth Annual Research Meeting*; June 8–10, 2008; Washington, DC.

**Gibson TB**. Estimating out-of-pocket pharmaceutical expenditures under the new Medicare drug law for patients with mental disorders—An analysis of claims data from retiree medical plans.

*AcademyHealth Annual Research Meeting*; June 25–27, 2006; Washington, DC.



**Gibson TB, Ozminkowski RJ, Mark T, Costa L.** Estimating out-of-pocket pharmaceutical expenditures under the new Medicare drug law for patients with mental disorders—An analysis of claims data from retiree medical plans.

*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.

**Mark T.** Medicare Part D and dual eligibles.

*13th NIMH Biennial Research Conference on the Economics of Mental Health—Pharmacoeconomics*; September 25–26, 2005; Bethesda, MD.

**Mark TL, Gibson TB, McGuigan KA.** Unintended results of step therapy: Increase in patients' inpatient, outpatient, and emergency room utilization and cost despite medication cost reduction.

*AcademyHealth Annual Research Meeting*; June 8–10, 2008; Washington, DC.

**Mark T, Gibson TB, McGuigan K.** The effects of step therapy: Looking beyond impacts on prescribing rates and costs.

*ISPOR 13th Annual International Meeting*; May 3–7, 2008; Toronto, Canada.

*AcademyHealth Annual Research Meeting*; June 8–10, 2008; Washington, DC.

**Mark TL, Ozminkowski RJ.** The Medicare donut hole: To what extent are your products at risk?

*2005 Pharmaceutical Management Science Association Conference*; May 15–18, 2005; Nashville, TN.

**Mucha L, Axelsen K, Masia N.** Per-patient-per-month drug costs in Medicare Part D protected classes.

*Academy Health Annual Conference*; June 3–5, 2007; Orlando, FL.

**Ozminkowski R.** The Medicare donut hole: Who and how much will fall in?

*AMCP 17<sup>th</sup> Annual Meeting & Showcase*; April 20–23, 2005; Denver, CO.

**Ozminkowski RJ, Hawkins K, Peters J, Marder WD.** The impact of Medicare's prescription drug law: Empirical estimates.

*AcademyHealth Annual Research Meeting*; June 6–8, 2004; San Diego, CA.

## Health and Productivity Management

---

Bowen HM, DeJoy DM, Wilson MG, **Goetzel RZ**, Roemer EC, **Ozminkowski RJ.** Modifying the worksite environment to support individual behavior change.

*American Public Health Association 136th Annual Meeting*; October 25–29, 2008; San Diego, CA.

Christaldi J, Bowen H, Baker K, DeJoy DM, Wilson MG, **Goetzel RZ, Ozminkowski RJ.** Employee perceptions of an environmental obesity management program.

*American Public Health Association 136th Annual Meeting*; October 25–29, 2008; San Diego, CA.



**Goetzel RZ**, Roemer EC, **Pei X**, **Short ME**, **Tabrizi MJ**, Wilson MG, DeJoy DM, Craun BA, Tully KJ, White JM, Baase CM. Second-year results of an obesity prevention program at the Dow Chemical Company.

*American Occupational Health Conference*; May 2–5, 2010; Orlando, FL.

**Henke RM**, **Carls GS**, **Short ME**, **Pei X**, **Wang S**, Moley S, Sullivan M, **Goetzel RZ**. The relationship between health risks and health and productivity costs at Pepsi Bottling Group.

*AcademyHealth Annual Research Meeting*; June 27–29, 2010; Boston, MA.

**Mark T**, **Cao Z**, **Johnston S**. The workplace burden of smoking in the United States.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting*; August 16–19, 2009; Providence, RI.

**Mark T**, **Johnston S**, **Cao Z**. The workplace burden of smoking.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL.

**Pei X**, **Goetzel RZ**, **Short ME**, Roemer EC, Luisi D, Quitoni K, **Tabrizi MJ**, Liss-Levinson RC, Samoly DK. Two-year evaluation of a public-private partnership for a health promotion program at the workplace.

*American Public Health Association 136th Annual Meeting*; October 25–29, 2008; San Diego, CA.

**Short ME**, **Pei X**, **Goetzel RZ**, **Tabrizi MJ**, **Ozminkowski RJ**. How do self-reported healthcare utilization and absenteeism measures compare to administrative data?

*American Public Health Association 136th Annual Meeting*; October 25–29, 2008; San Diego, CA.

Silverman SL, **Mucha L**, Brandenburg N. The relative impact of fibromyalgia and rheumatoid arthritis on medical expenditures, absenteeism and short term disability benefits.

*70<sup>th</sup> Annual Meeting of the American College of Rheumatology*; November 10–15, 2006; Washington DC.

## Infectious Diseases

---

Barr CE, **Schulman KL**, Iacuzio DA. Oseltamivir reduces the risk of pneumonia following influenza among pediatric patients.

*46<sup>th</sup> Annual International Interscience Conference on Antimicrobial Agents and Chemotherapy*; September 27–30, 2006; San Francisco, CA.

Barr CE, **Schulman KL**, Iacuzio DA. Reduction in the risk of pneumonia following oseltamivir use for influenza among pediatric patients.

*American Academy of Pediatrics National Conference and Exhibition*; October 7–10, 2006; Atlanta, GA.

*American College of Emergency Physicians Research Forum*; October 15–18, 2006; New Orleans, LA.



Blumentals WA, **Schulman K**. Oseltamivir reduces the risk of influenza complications in vaccinated children.

*47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, The American Society for Microbiology; September 17–20, 2007; Chicago, IL.*

**Bonafede M**, Pan K, Wilson K, Solomon M, Spiegel B, Beam C, Chakravarti P. Direct and indirect costs of hepatitis C virus (HCV): Comparison of non-HCV, untreated HCV, and peg-RBV treated HCV cohorts.

*ISPOR 15th Annual International Meeting; May 15–19, 2010; Atlanta, GA.*

**Bonafede M**, Suaya J, **Wilson K**, Mannino D, Polsky D. US incidence and excess cost of community-acquired pneumonia in a large commercially insured working-age population.

*Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2011; Chicago, IL.*

Iacuzio D, **Schulman K**, Barr CE. Reduction in the risk of pneumonia and hospitalization following oseltamivir use for influenza.

*14<sup>th</sup> Annual Congress on Women's Health; June 3–6, 2006; Hilton Head Island, SC.*

**Mucha L**, Seal B, **Lenhart G**, Asche C. Direct and indirect costs associated with treatment episodes of community acquired pneumonia.

*2006 American Society of Health-System Pharmacists Midyear Clinical Meeting; December 2–7, 2006; Anaheim, CA.*

**Mucha L**, Seal B, **Lenhart G**, Asche C. Initial antibiotic treatment and associated costs for community-acquired pneumonia.

*CHEST 2006, American College of Chest Physicians Annual Meeting; October 21–26, 2006; Salt Lake City, UT.*

Nichol KL, Rousculp MD, **Palmer L**, **Johnston S**, Mahadevia PJ. Influenza-like illness and employee productivity: Results from the Child and Household Influenza-illness and Employee Function (CHIEF).

*48th ICAAC/46th IDSA Annual Meeting; October 25–28, 2008; Washington, DC.*

Orzeck E, **Schulman K**, Blumentals W. Effect of oseltamivir on influenza-related complications and hospitalizations in patients with diabetes.

*67th Scientific Session of the American Diabetes Association; June 22–26, 2007; Chicago, IL.*

Piedra P, **Schulman K**, Blumentals WA. Oseltamivir reduces the risk of influenza-related complications and hospitalization in children and adolescents with chronic medical conditions.

*47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, The American Society for Microbiology; September 17–20, 2007; Chicago, IL.*

Rousculp MD, **Palmer L**, **Johnston S**, Mahadevia PJ, Nichol KL. The child and household influenza-illness and employee function (CHIEF) study: Linking survey and claims data to understand disease impact on indirect costs.

*ISPOR 13th Annual International Meeting; May 3–7, 2008; Toronto, Canada.*



Rousculp MD, **Palmer L, Johnston S**, Mahadevia PJ, Nichol KL. Employees' willingness to pay for influenza vaccination of household members—Results from the child and household influenza-illness and employee function (CHIEF) study.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL. **(Best Poster Finalist)**

Rousculp MD, **Palmer L, Johnston SS**, Nichol KL, Mahadevia PJ. Attitudes and preferences regarding influenza prevention for children: Results from the Child and Household Influenza-illness and Employee Function (CHIEF) Study.

*2010 Pediatric Academic Societies' Annual Meeting*; May 1–4, 2010; Vancouver, Canada.

Rousculp MD, **Palmer L, Johnston SS**, Nichol KL, Mahadevia PJ. Attitudes regarding influenza vaccination of children: Results from the child and household influenza-illness and employee function (CHIEF) study.

*50th Annual Meeting of the European Society for Paediatric Research*; October 9–12, 2009; Hamburg, Germany.

Rousculp MD, **Palmer L, Johnston SS**, Nichol KL, Mahadevia PJ. Impact of a child's respiratory illness on employee productivity: Results from the child and household influenza-illness and employee function (CHIEF) study.

*The Pediatric Academic Societies*; May 2–5, 2009; Baltimore, MD.

*50th Annual Meeting of the European Society for Paediatric Research*; October 9–12, 2009; Hamburg, Germany.

**Schulman K, Song X, Shi N, Morandi N**. Variation in the use of neuraminidase inhibitors in the treatment of influenza.

*Academy Health Annual Conference*; June 3–5, 2007; Orlando, FL.

Treanor J, **Song X**, Blumentals WA. The safety of oseltamivir treatment in children and adolescents: Analysis of healthcare claims data from six influenza seasons.

*47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, The American Society for Microbiology*; September 17–20, 2007; Chicago, IL.

*American Academy of Pediatrics 2007 National Conference and Exhibition*; October 26–30, 2007; San Francisco, CA.

## Mental Health

---

**Bagalman JE, Gibson TB**, Yaldo A, **Cao Z**, Durkin MB. Burden of multiple psychiatric comorbidities for children and adolescents with attention-deficit/hyperactivity disorder in a Medicaid population.

*2009 U.S. Psychiatric & Mental Health Congress*; November 2–5, 2009; Las Vegas, NV.

**Chang S, Mark TL**, Brandenburg N. Economic burden of generalized anxiety disorder (GAD) and other anxiety disorders.

*ISPOR 10<sup>th</sup> Annual International Meeting*; May 15–18, 2005; Washington, DC.



**Gibson TB**, Chen CC, Kim E, Jing Y, **Chu BC**, **Wang SS**, **Bagalman JE**, Tran QV, Whitehead R. Adherence and persistence to second-generation atypical antipsychotic medications in patients enrolled in employer-sponsored health plans.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL.

Hodgkins P, Sasané R, **Montejano L**, **Huse D**. Burden of illness and comorbidities in adult patients with attention-deficit/hyperactivity disorder (ADHD).

*American Psychiatric Association Institute on Psychiatric Services*; October 8–11, 2009; New York, NY.

Jing Y, **Johnston SS**, **Fowler R**, Bates J, Forbes RA, Hebden T. Retrospective study of time to psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder newly initiating a second generation antipsychotic.

*2010 Institute on Psychiatric Services*; October 14–17, 2010; Boston, MA.

**Levit KL**. Projections of mental health and substance abuse spending, 2004–2014.

*AcademyHealth Annual Research Meeting*; June 8–10, 2008; Washington, DC.

Locklear J, Wade S, **Palmer LA**, Järbrink K, Toghianian S. Real-world treatment patterns and healthcare resource utilization in generalised anxiety disorder (GAD): A retrospective United States database analysis.

*ISPOR 13<sup>th</sup> Annual European Congress*; November 6–9, 2010; Prague, Czech Republic.

**Mark T**. An examination of psychiatric patients treated in general hospitals specialty units and scatter beds.

*AcademyHealth Annual Research Meeting*; June 8–10, 2008; Washington, DC.

**Mark T**. For what diagnoses are psychotropic medications being prescribed? Implications for understanding off-label prescribing.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting*; August 19–22, 2010; Brighton, UK.

**Mark T**. National mental health medication prescribing patterns.

*Academy Health Annual Conference*; June 3–5, 2007; Orlando, FL.

**Mark T**. Recent trends in psychiatric prescription drug spending

*3rd Biennial Conference of the American Society of Health Economists*; Jun 20–23, 2010; Ithaca, NY.

**Mark T**. Revisiting the de facto US mental health services system.

*AcademyHealth Annual Research Meeting*; June 27–29, 2010; Boston, MA.

**Mark T**. What drove the dramatic slowdown in psychiatric drug spending growth in the United States.

*ISPOR 16th Annual International Meeting*; May 21–25, 2011; Baltimore, MD.



**Mark TL.** General hospitals with and without psychiatric units: How much and for whom? Psychiatric unit beds: How much and for whom?

*Agency for Health Care Research and Quality Annual Meeting*; September 14, 2009; Bethesda, MD.

**Mark T, Chang S.** Outpatient continuation of inpatient antipsychotic prescriptions: A linked data analysis.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting*; August 16–19, 2009; Providence, RI.

**Mark T, Coffey R.** The effect of behavioral carve-outs on pharmaceutical use and expenditures.

*ISPOR 9<sup>th</sup> Annual International Meeting*; May 16–19, 2004; Arlington, VA.

**Mark TL, Gibson TB, Chu BC, McGuigan K.** The effects of antidepressant step-therapy protocols on pharmaceutical and medical utilization and expenditures.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL.

**Mark T, Joish V, Hay J, Sheehan D, Choi CJ, Johnston S, Cao Z.** Impact of drug-drug interactions on compliance among elderly antidepressant users.

*American Academy of Geriatric Psychiatry Annual Meeting*; Mar 5–8, 2009; Honolulu, HI.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting*; August 16–19, 2009; Providence, RI.

**Mark TL, Joish VN, Hay JW, Sheehan D, Choi JC, Johnston S, Cao Z.** Unintended consequences of current antidepressant use in a geriatric population: The burden of side-effects on adherence and costs.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL.

**Mark TL, Joish VN, Hay JW, Sheehan D, Choi JC, Johnston S, Cao Z.** Unintended consequences of current antidepressant use in a geriatric population: Drug-drug interactions and their implications for adherence.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL.

**Mark TL, Joish VN, Hay J, Sheehan DV, Johnston S, Cao Z.** Burden of current antidepressant use in geriatric population.

*American Society of Consultant Pharmacists 39th Annual Meeting and Exhibition, Senior Care Pharmacy '08*; November 19–22, 2008; New Orleans, LA.

**Mark T, Long S.** Recent trends in psychiatric prescription drug spending.

*ISPOR 13<sup>th</sup> Annual European Congress*; November 6–9, 2010; Prague, Czech Republic.

**Mark TL, Long S.** Psychotherapy use among adolescents prescribed antidepressants and antipsychotics.

*24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*; August 17–20, 2008; Copenhagen, Denmark



**Mark TL**, Panish J, Mao L, **Montejano LB**, Dirani R, Fastenau J, Starr HL. Characteristics of patients in community behavioral health organizations receiving two injectable forms of atypical antipsychotic medications as compared with other antipsychotics.

*ISPOR 16th Annual International Meeting; May 21–25, 2011; Baltimore, MD.*

**Mark T**, Vandivort-Warren R, Buck J, King E, Harwood R, Levit K, **Coffey R**. Mental health and substance abuse spending by age.

*The Nineteenth NIMH Conference on Mental Health Services Research MHSR 2007; July 23–24, 2007; Washington, DC.*

**Montejano L**, Sasane R, Hodgkins P, **Huse D**. Adult ADHD in the United States: A comparison of 2 methods to estimate prevalence.

*ISPOR 14th Annual International Meeting; May 16–20, 2009; Orlando, FL.*

**Montejano L**, Sasané R, Hodgkins P, **Huse D**. Burden of illness and comorbidities in adult patients with attention-deficit/hyperactivity disorder.

*ISPOR 12th Annual European Congress; October 24–27, 2009; Paris, France.*

**Montejano L**, Sasané R, Hodgkins P, **Huse D**. Burden of illness and comorbidities in adult patients with attention-deficit/hyperactivity disorder compared to patients with depression.

*American Psychiatric Association Institute on Psychiatric Services; October 8–11, 2009; New York, NY.*

**Montejano L**, Sasane R, Hodgkins P, **Huse D**. Risk of injury in adults with attention-deficit hyperactivity disorder.

*ISPOR 14th Annual International Meeting; May 16–20, 2009; Orlando, FL.*

Panish JM, Dirani R, **Mark T**, **Montejano L**, Starr HL, Mao L, Fastenau J. Schizophrenia and bipolar I disorder registry: Building knowledge from community behavioral health organizations (CBHOs).

*41st National Council Mental Health and Addictions Conference; May 2–4, 2011, San Diego, CA.*

Slabaugh SL, Durkin MB, **Montejano LB**. Factors associated with healthcare costs in a population of commercially insured children and adolescents with attention deficit/hyperactivity disorder and psychiatric comorbidities.

*ISPOR 16th Annual International Meeting; May 21–25, 2011; Baltimore, MD.*

Starr HL, **Mark T**, Panish JM, Mao L, **Montejano L**, Fastenau J, Dirani R. Characteristics of patients in community behavioral health organizations receiving two injectable forms of atypical antipsychotic medications.

*164th Annual Meeting of the American Psychiatric Association; May 14–18, 2011; Honolulu, HI.*



## Neurology and Pain

---

Allen P, O'Calloway M, Kwong J, **Palmer L**. Burden of illness associated with restless legs syndrome: Findings from patients visiting primary-care settings in the USA.

*11th International Congress of Parkinson's Disease and Movement Disorders*; June 3–7, 2007; Istanbul, Turkey.

Allen P, O'Calloway M, Kwong J, **Palmer L**. Prevalence of restless legs syndrome in a primary-care population.

*11th International Congress of Parkinson's Disease and Movement Disorders*; June 3–7, 2007; Istanbul, Turkey.

Avidan A, **Palmer L**, Doan J, Baran R. Insomnia medication use in an elderly population and the risk of an accidental event.

*American Society for Health Systems Pharmacists Mid-Year Clinical Meeting*; December 2–6, 2007; Las Vegas, NV.

Avidan A, **Palmer L**, Doan J, Baran R. Risk of accidents in older adults taking medications for insomnia.

*The American Association for Geriatric Psychiatry Annual Meeting*; March 15, 2008; Orlando, FL.

Avidan AY, **Palmer LA**, Doan JF, Baran RW. Insomnia medication use and the probability of an accidental event in a commercial population.

*SLEEP 2008 22nd Annual Meeting of the Associated Professional Sleep Societies, LLC*; June 7–10, 2008; Baltimore, MD.

**Bonafede M, Johnson BH**, Crawley J, Hellmund R. The budget impact of lower GPA adherence in patients with chronic non-steroidal and cox-2 inhibitor use.

*ISPOR 16th Annual International Meeting*; May 21–25, 2011; Baltimore, MD.

Botteman MF, **Ozminkowski RJ, Wang S**, Pashos CL, Foley DJ, Schaefer K. Cost-effectiveness of longer-term treatment with eszopiclone 3 MG in adults with primary insomnia.

*ISPOR 10<sup>th</sup> Annual International Meeting*; May 15–18, 2005; Washington, DC.

Brandenburg N, **Mucha L**, Silverman S. Impact of fibromyalgia on medical care expenditures and productivity losses.

*26th Annual Scientific Meeting, American Pain Society*; May 5–7, 2007; Washington, DC.

Calloway M, **Palmer L**. Patient reported satisfaction with prescription and over-the-counter treatments for restless legs syndrome (RLS).

*13<sup>th</sup> Annual International Society of Quality of Life Research Meeting*; October 11–14, 2006; Lisbon, Portugal.



Calloway M, **Palmer L**. Satisfaction with ropinirole treatment for restless legs syndrome (RLS): Relationship between disease duration and satisfaction.

*13<sup>th</sup> Annual International Society of Quality of Life Research Meeting*; October 11–14, 2006; Lisbon, Portugal.

Calloway M, **Palmer L**. Treatment satisfaction with ropinirole in patients who had discontinued prior restless legs syndrome (RLS) therapies: The RLS select study.

*13<sup>th</sup> Annual International Society of Quality of Life Research Meeting*; October 11–14, 2006; Lisbon, Portugal.

Cuffel B, **Mucha L**, Del Valle M, **Wang, S**. Comparison of cholinesterase inhibitor utilization patterns in Alzheimer's disease and the impact of healthcare expenditures.

*10<sup>th</sup> European Federation of Neurological Societies Congress*; September 2–5 2006; Glasgow, UK.

Curtice TG, **Long SR**, **Baser O**, **Montejano LB**, Lobo F. Economic burden of restless legs syndrome in a privately-insured population.

*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.

**Curkendall S**, Wang C, **Johnson BH**, **Cao Z**, Preblich R, **Torres A**, Knappertz V, Gondek K. Health economic impact of early treatment of multiple sclerosis with disease modifying therapy.

*ISPOR 15<sup>th</sup> Annual International Meeting*; May 15–19, 2010; Atlanta, GA. **(Best Poster Finalist)**

**Curkendall S**, Wang C, **Johnson B**, Preblich R, **Torres A**, Knappertz V, Gondek K. Identifying early presentation of multiple sclerosis: A challenge using insurance claims data.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting*; August 19–22, 2010; Brighton, UK.

Dworkin RH, White RE, **Hawkins K**. Healthcare expenditures in patients with herpes zoster pain and postherpetic neuralgia.

*25<sup>th</sup> Annual Scientific Meeting of the American Pain Society*; May 3–6, 2006; San Antonio, TX.

**Foley K**, Kalsekar A, **Baser O**, Walsh J. Healthcare costs of patients with insomnia: How much do the health plan and patient pay?

*SLEEP 2007 21<sup>st</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC*; June 9–14, 2007; Minneapolis, MN.

Forlenza JB, **Durden E**, **Johnston S**, Ascher S, Wan GJ. Work loss and associated costs in U.S. employees with epilepsy receiving multiple antiepileptic drugs.

*Academy of Neurology Annual Meeting*; April 10–17, 2010; Toronto, Canada.

Forlenza JB, **Johnston S**, Costa LA, **Lenhart G**, **Durden E**, Ascher S, Grinspan A. Treatment continuation patterns, resource use, and costs among patients with epilepsy in a Medicaid population.

*Academy of Neurology Annual Meeting*; April 10–17, 2010; Toronto, Canada.



Grinspan A, **Johnston S**, Costa LA, **Lenhart G**, **Durden E**, Ascher S, Forlenza JB. Factors associated with time to discontinuation of antiepileptic drug (AED) treatment in a commercially insured population of patients with epilepsy receiving 2 or 3 AEDs.

*American Epilepsy Society 63rd Annual Meeting*; December 4–8, 2009; Boston, MA.

**Hawkins K**, Grossman P, **Orsini LS**, **Ozminkowski RJ**, **Baser O**. Examination of total healthcare expenditures for patients on long acting opioid medications for the treatment of chronic pain in the Medicaid population.

*ISPOR 9<sup>th</sup> Annual International Meeting*; May 16–19, 2004; Arlington, VA.

**Hawkins K**, Rupnow M, **Wang S**. Direct cost burden of migraine among members of U.S. employer groups.

*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.

**Hawkins K**, Rupnow M, **Wang S**. The indirect cost burden of migraine among several large U.S. employers.

*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.

**Hawkins K**, White R, Dworkin R, O'Connor A, **Baser O**. The spectrum of healthcare costs associated with herpes zoster: Acute pain vs. postherpetic neuralgia.

*ISPOR 12th Annual International Meeting*; May 19–23, 2007; Arlington, VA.

Hutchings A, Calloway M, Choy E, Hunter J, Jordan J, Zhang Y, **Long S**, **Palmer L**. The Longitudinal Examination of Arthritis Pain (LEAP) Pilot Study: Relation of self-rated joint pain fluctuations to health outcomes.

*70<sup>th</sup> Annual Meeting of the American College of Rheumatology*; November 10–15, 2006; Washington DC.

**Johnson BH**, **Foley K**, Patel A, Atwood C, Sander SD, Shah H. Assessment of treatment patterns and healthcare expenditures of restless leg syndrome (RLS) patients newly started on a dopamine agonist vs. other agent.

*The Movement Disorder Society's 12th International Congress on Parkinson's Disease and Movement Disorders*; June 22–26, 2008; Chicago, IL.

**Johnston S**, Costa L, **Durden E**, Biondi D, Forlenza J. Treatment continuation and discontinuation patterns, resource utilization and costs among patients with epilepsy.

*American Society of Health-Systems Pharmacists 43rd Annual Midyear Clinical Meeting*; December 7–11, 2008; Orlando, FL.

Kim Le T, **Montejano LB**, **Cao Z**, Zhao Y, Ang D. Direct healthcare costs associated with osteoarthritis.

*ISPOR 16th Annual International Meeting*; May 21–25, 2011; Baltimore, MD.

Kim Le T, **Montejano L**, Johnston J, Robinson R, Krohn K. Analgesic utilization by osteoarthritis patients before and after total hip arthroplasty or total knee arthroplasty.

*The American Academy of Pain Medicine 26th Annual Meeting*; February 3–6, 2010; San Antonio, TX.



Kim Le T, **Montejano L**, Johnston J, Ang D. Comparison of healthcare expenditures associated with different chronic pain conditions.

*The American Academy of Pain Medicine 26th Annual Meeting*; February 3–6, 2010; San Antonio, TX.

Knoth R, Shah S, **Margolis J**, Alvir J, **Lenhart G**. Examining the effect of Alzheimer's disease medication cost-share burden on adherence and persistence on these medications.

*Alzheimer's Association International Conference on Alzheimer's Disease*; July 16–21, 2011; Paris, France.

**Margolis J, Cao Z, Fowler R**, Harnett J, Silverman SL. Comparison of direct and indirect costs in employees with painful diabetic peripheral neuropathy treated with pregabalin or duloxetine.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA.

**Margolis J, Cao Z**, Onukwugha E, Sanchez R, Alvir J, Joshi AV, Mullins D. Effects of prior authorization for pregabalin in commercial health plans.

*AMCP Annual Meeting*; April 7–10, 2010; San Diego, CA.

**Margolis J, Johnson, B**, Fowler R, Dastani H. Disease-modifying drug initiation patterns in newly diagnosed MS patients.

*Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting*; June 2–6, 2010; San Antonio, TX.

**Margolis J, Johnson B**, Fowler R, Mody-Patel N, Malhotra M. Time to initiation of disease modifying therapy for multiple sclerosis patients in a commercial managed-care population.

*American Academy of Neurology 61st Annual Meeting*; April 25–May 2, 2009; Seattle, WA.

**Montejano L, Foley K**, Sander S, Patel A, Shah H, Brunton S. Assessment of drug-drug interaction potential among patients with Parkinson's disease.

*XVII WFN World Congress on Parkinson's Disease and Related Disorders*; December 9–13, 2007; Amsterdam, The Netherlands.

**Montejano BL, Long SR, Baser O**, Lobo F, Curtice TG. Restless legs syndrome: Identification of treated patients in a large claims database.

*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.

**Mucha L, Fowler R, Bonafede M**. The incremental effect of Alzheimer's disease on direct healthcare costs and utilization in a Medicaid population.

*Alzheimer's Association International Conference on Alzheimer's Disease*; July 16–21, 2011; Paris, France.

**Mucha L, McLaughlin TP, Racketta J, Bonafede M, Fowler R**. Central nervous system (CNS) comorbidities and concomitant drug use in a Medicaid AD population.

*2010 International Conference on Alzheimer's Disease (ICAD)*; July 10–15, 2010; Honolulu, HI.



**Mucha LM**, Cuffel B, McCrae T, **Mark T**, **Wang S**. Utilization of cholinesterase inhibitors in the treatment of Alzheimer's disease.

*AMCP 2005 Educational Conference*; October 5–8, 2005; Nashville, TN.

**Orsini LS**, Kennedy S, Castelli-Haley J, **Huse DM**. Healthcare utilization and expenditures among Medicaid patients with Parkinson's disease.

*ISPOR 9<sup>th</sup> Annual International Meeting*; May 16–19, 2004; Arlington, VA.

**Ozminkowski RJ**. Using medical claims data and clinical literature to forecast the impact of adding a new drug onto the formulary: A case study of insomnia treatment.

*19<sup>th</sup> Annual Meeting of the Associated Professional Sleep Societies*; June 18–23, 2005; Denver, CO.

**Ozminkowski RJ**, **Lenhart G**, **Wang S**, et al. Forecasting the impact of adding new drug on formulary using medical claims data and clinical literature: A case study for insomnia treatment.

*ISPOR 10<sup>th</sup> Annual International Meeting*; May 15–18, 2005; Washington, DC.

**Ozminkowski RJ**, **Lenhart G**, **Wang S**, et al. Using medical claims data and clinical literature to forecast the impact of adding a new drug onto the formulary: A case study of insomnia treatment.

*AMCP 17<sup>th</sup> Annual Meeting & Showcase*; April 20–23, 2005; Denver, CO.

**Palmer LA**, **Fowler R**, **Shi N**, Dastani H, Abouzaid S, Kim E. Impact of patient cost-sharing arrangements for disease modifying therapies on treatment compliance among U.S. patients with multiple sclerosis.

*ISPOR 14th Annual European Congress*; November 5–8, 2011; Madrid, Spain.

Robinson R, **Montejano LB**, **Ruiz K**, **Lenhart G**. The economic burden of interstitial cystitis and painful bladder syndrome.

*American Urological Association Annual Meeting*; May 14–19, 2011; Washington, DC.

Sarsour K, **Foley K**, Kalsekar A, Walsh JK. The prevalence of insomnia symptoms and comorbidities across Insomnia Severity Index categories in a community-based sample.

*SLEEP 2008 22nd Annual Meeting of the Associated Professional Sleep Societies, LLC*; June 7–10, 2008; Baltimore, MD.

Silverman S, **Mucha L**, Brandenburg N. Utilization and costs of pharmacologic interventions for fibromyalgia and its comorbidities.

*2007 Annual Meeting, American Psychiatric Association*; May 19–24, 2007; San Diego, CA.

Walsh JK, **Foley K**, Kalsekar A, Sarsour K. Frequency and duration of use of prescription and over-the-counter sleep-promoting medications.

*SLEEP 2008 22nd Annual Meeting of the Associated Professional Sleep Societies, LLC*; June 7–10, 2008; Baltimore, MD.

White R, **Palmer L**, **Johnson B**, **Fowler R**. The cost of herpes zoster among hematopoietic stem cell transplant recipients.

*American Society for Blood and Marrow Transplantation (2010 BMT Tandem Meetings)*; February 24–28, 2010; Orlando, FL.



## Oncology

---

Barlev A, **Song X**, **Ivanov B**. Costs of skeletal-related events among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.

*The 44th ASHP Midyear Clinical Meeting*; December 6–10, 2009; Las Vegas, NV.

**Baser O**, **Song X**, Henk HJ, **Long SR**, Daniel G, Kamat S, Crown W. Comparative erythropoiesis stimulating agents (ESA) drug costs in propensity score matched cohorts of anemic cancer patients undergoing chemotherapy.

*ISPOR 13th Annual International Meeting*; May 3–7, 2008; Toronto, Canada.

Bonthapally V, Ganguli A, **Landsman-Blumberg P**, **McMorrow D**, Ray S. Healthcare resources and costs across lines of therapies in insured patients with metastatic breast cancer in the United States.

*ISPOR 14th Annual European Congress*; November 5–8, 2011; Madrid, Spain.

Cartwright T, **Schulman KL**, Zelt S, Chu E. Cost of chemotherapy for patients with metastatic colorectal cancer treated with capecitabine plus oxaliplatin or 5-fluorouracil plus oxaliplatin.

*2009 Gastrointestinal Cancers Symposium*; Jan 15–17, 2009; San Francisco, CA.

**Chang S**, **Long S**, Kutikova L, Bowman L, Crown WH. Economic burden of pancreatic cancer and treatment failure.

*ISPOR 9<sup>th</sup> Annual International Meeting*; May 16–19, 2004; Arlington, VA.

Chu E, Cartwright T, Wei W, **Schulman KL**. Cost of care among patients with colorectal cancer: What needs to be included?

*AMCP 2008 Educational Meeting*; October 15–18, 2008; Kansas City, MO.

Chu E, **Shi N**, Wei W, Cartwright T. Costs associated with capecitabine or 5-fluorouracil monotherapy among patients with colorectal cancer in the adjuvant setting.

*2009 Gastrointestinal Cancers Symposium*; Jan 15–17, 2009; San Francisco, CA.

Chu E, **Song X**, Zelt S. A claims database cost comparison analysis of capecitabine in the treatment of patients with colon or rectal cancer (CRC).

*2008 Gastrointestinal Cancers Symposium*; January 25–27, 2008; Orlando, FL.

Chu E, **Schulman KL**, Zelt S. Capecitabine use in patients with colon and rectal cancer (CRC): A claims database analysis of treatment.

*2008 Gastrointestinal Cancers Symposium*; January 25–27, 2008; Orlando, FL.

Chu E, **Schulman KL**, Zelt S, Cartwright T. Cost of chemotherapy for patients with metastatic colorectal cancer treated with capecitabine or 5-fluorouracil monotherapy.

*2009 Gastrointestinal Cancers Symposium*; Jan 15–17, 2009; San Francisco, CA.



Demetri G, von Mehren M, Joensuu H, **Huse D, Lenhart G**, Feng W, Blanke C. Relation between gastrointestinal stromal tumor (GIST) response to imatinib therapy and long-term survival.

*29<sup>th</sup> European Society of Medical Oncology Congress*; September 29–October 3, 2006; Istanbul, Turkey.

**Foley KA**, Wang PF, Barber B, **Long SR, Bagalman JE**, Zhao Z. Economic impact of severe infusion reactions in patients with colorectal cancer treated with cetuximab.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL.

Harris L, **Schulman KL**, Zelt S. Chemotherapy related expenditure in women with metastatic breast cancer treated with capecitabine or gemcitabine.

*31st Annual San Antonio Breast Cancer Symposium*; December 10–14, 2008; San Antonio, TX.

Harris L, Wei W, **Morandi N**. Chemotherapy related expenditure in women with metastatic breast cancer treated with capecitabine or vinorelbine.

*31st Annual San Antonio Breast Cancer Symposium*; December 10–14, 2008; San Antonio, TX.

**Huse D, Lenhart G**, Feng W, Blanke C, Joensuu H, von Mehren M, Demetri G. Cost-effectiveness of imatinib in the treatment of gastrointestinal stromal tumors.

*29<sup>th</sup> European Society of Medical Oncology Congress*; September 29–October 3, 2006; Istanbul, Turkey.

**Johnston SS**, O'Malley CD, **Palmer LA, Chu BC**, Richardson LC. Fractures in breast cancer patients treated with hormonal therapies: A retrospective cohort study.

*3rd North American Congress of Epidemiology*; June 21–24, 2011; Montreal, Canada.

Krupski TL, **Foley KA, Baser O, Long S**, Macarios D, Litwin MS. Androgen deprivation therapy increased fracture risk in men with prostate cancer.

*American Urological Association 2006 Annual Meeting*; May 20–24, 2006; Atlanta, GA.

Krupski TL, **Foley KA, Baser O, Long S**, Macarios D, Litwin MS. Health care cost associated with prostate cancer, androgen deprivation therapy, and bone complications.

*American Urological Association 2006 Annual Meeting*; May 20–24, 2006; Atlanta, GA.

Lee DW, Stang PE, Goldberg GA, **Haberman M**. Resource use and cost of diagnostic workup of women with suspected breast cancer.

*ISPOR Annual European Congress*; October 20–23, 2007; Dublin, Ireland.

Logothetis C, De Bono JS, Molina A, Basch EM, Fizazi K, North S, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, **Gagnon DD**, Dhawan R, Rothman M, Hao Y, Liu CS, Kheoh TS, Scher HI, Haqq CM. Effect of abiraterone acetate (AA) on pain control and skeletal related events (SRE) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase 3 study.

*ASCO Annual Meeting 2011*; June 3–7, 2011; Chicago, IL.



**Long SR, Foley KA, Wang PF, Barber B, Zhao Z.** The economic burden associated with metastatic colorectal cancer.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL.

**Long SR, Song X, Barber B, Kassed CA, Zhao Z.** Infusion reactions in patients treated with anti-EGFR monoclonal antibody therapies for metastatic colorectal cancer: Rates and impact from literature review.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA.

**Mark T, Fortner B, Johnson G, Song X.** Improving cancer symptom management through information technology.

*AcademyHealth Annual Research Meeting*; June 25–27, 2006; Washington, DC.

**Mark T, Fortner B, Johnson G, Song X.** Lessons learned from a randomized control trial of the supportive oncology services e/tablet technology.

*Critical Issues in eHealth Research Conference*; June 9–10, 2005; Bethesda, MD.

**Mark T, Fortner B, Johnson G.** A multi-part evaluation of a cancer symptom management information technology system.

*ISPOR 12th Annual International Meeting*; May 19–23, 2007; Arlington, VA.

**Mark T, Fortner B, Johnson G, Ryan K.** Patient and provider perceptions of an e/tablet technology to screen and education oncology patients.

*NIH Critical Issues in e-Health: Toward Quality Patient-Centered Care*; September 11–12, 2006; Bethesda, MD.

**Mark TL, McKenzie RS, Fastenau JM, Piech CT.** Patient benefits of early hemoglobin response following initiation of erythropoietic agents in breast cancer patients with chemotherapy-related anemia.

*Lynn Sage Breast Cancer Symposium*; October 18–31, 2004; Chicago IL.

**Mark TL, McKenzie S, Fastenau J, Piech C.** Patient benefits of early hemoglobin response following initiation of erythropoietic agents in elderly patients with chemotherapy-related anemia.

*International Society of Geriatric Oncology*; October 15–16, 2004; San Francisco, CA.

**Mark TL, McKenzie RS, Piech CT.** Better early and overall hematologic outcomes and lower drug cost with epoetin alfa compared with darbepoetin alfa in patients with chemotherapy-related anemia.

*Academy of Managed Care Pharmacy's 16th Annual Meeting*; March 31–April 3, 2004; San Francisco, CA.

*American College of Clinical Pharmacy*; October 24–27, 2004; Dallas, TX.

**Mark TL, McKenzie RS, Piech CT.** Better early and overall hematologic outcomes with epoetin alfa compared with darbepoetin alfa in patients with gynecologic malignancies.

*Society of Gynecologic Oncologists' Annual Meeting*; February 7–11, 2004; San Diego, CA.



**Mark TL, McKenzie RS, Piech CT.** Epoetin alfa compared with darbepoetin alfa provides significantly higher hemoglobin rise and overall lower cost in treating chemotherapy-related anemia in patients with breast cancer.

*American Society of Breast Disease's Symposium; April 23–25, 2004; Boston, MA.*

*Lynn Sage Breast Cancer Symposium; October 28–31, 2004; Chicago, IL.*

McKenzie RS, **Mark TL**, Piech CT. Better early and overall hematologic outcomes and lower drug cost with epoetin alfa compared to darbepoetin alfa in colorectal cancer patients.

*American Society of Clinical Oncology Gastrointestinal Cancer Symposium; January 22–24, 2004; San Francisco, CA.*

*Gastrointestinal Oncology Conference; July 8–10, 2004; Arlington, VA.*

McKenzie RS, **Mark TL**, Piech CT. Evidence-based comparative assessment of epoetin alfa and darbepoetin alfa in elderly patients (age > 65) with chemotherapy-related anemia.

*Geriatric Oncology Consortium Meeting; September 9–11, 2004; Washington, DC.*

*International Society of Geriatric Oncology; October 15–16, 2004; San Francisco, CA.*

**Meyer N, Weldon D, Huse DM.** Trends in chemotherapy and biologic treatment of US colorectal cancer patients.

*ISPOR 14th Annual European Congress; November 5–8, 2011; Madrid, Spain.*

Mortimer J, **Schulman K**, Kohles JD. Patterns of IV bisphosphonate use in the united states in the treatment of breast cancer metastatic to bone.

*The 29th Annual San Antonio Breast Cancer Symposium; December 14–17, 2006; San Antonio, TX.*

Rugo H, **Montejano LB**, Zelt S. Capecitabine is associated with fewer adverse events than other standard therapies in patients with breast cancer: Data from a clinical practice database.

*The 2007 Breast Cancer Symposium, American Society of Clinical Oncology; September 7–8, 2007; San Francisco, CA.*

Rugo H, **Schulman KL**, Zelt S. Cost comparison of capecitabine in the treatment of patients with breast cancer: An analysis of treatment patterns from a claims database.

*30th Annual San Antonio Breast Cancer Symposium; December 13–16, 2007; San Antonio, TX.*

**Schulman KL, Lenhart G, Torres A, Wilson K, Huse DM.** Increasing financial burden in patients with metastatic colorectal cancer.

*AcademyHealth Annual Research Meeting; June 28–30, 2009; Chicago, IL.*

Shorr AF, **Bonafede MK, Johnson BH**, Horblyuk R. Real-world effectiveness of antithrombotic agents for inpatient treatment of venous thromboembolism.

*XXII Congress of the International Society on Thrombosis and Haemostasis; July 11–16, 2009; Boston, MA.*



Showalter TN, Teti KA, **Foley KA**, Keith SW, Trabulsi EJ, Dicker A, Lallas CD, Pizzi L, Gomella LG. Do urologists and radiation oncologists agree on adjuvant radiation therapy for prostate cancer? A Web-based patterns-of-care survey.

*ASCO 2011 Genitourinary Cancers Symposium*; February 17–19, 2011; Orlando, FL.

**Song X**, Barleve A, **Ivanov B**. Hospital costs of skeletal related events among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.

*AMCP Educational Symposium*; Oct 7–10, 2009; San Antonio, TX.

**Song X**, **Fowler R**, **Ruiz K**, Hurley D, Barron R. The impact of neutropenic complications on short-term disability in patients with cancer receiving chemotherapy.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL. **(Best Poster Finalist)**

**Song X**, **Varker H**, Eichelbaum M, Kaiser R, Stopfer P, Shahidi M, Wilson K, Finnern HW. Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.

*35th European Society of Medical Oncology Congress*; October 8–12, 2010; Milan, Italy.

**Song X**, Zhao Z, Barber B, Gregory C, **Cao Z**, Gao S. Characterizing medical care during disease phases in metastatic colorectal cancer.

*ASCO Annual Meeting*; June 4–8, 2010; Chicago, IL.

**Song X**, Zhao Z, Barber B, Gregory C, **Cao Z**, Gao S. Cost of illness for patients with metastatic colorectal cancer.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA. **(Best Poster Finalist)**

Sternberg CN, Scher HI, Molina A, North S, Mainwaring P, Hao Y, **Gagnon D**, Kheoh T, Haqq CM, de Bono JS. Fatigue improvement/reduction with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: Results from the COU-AA-301 Phase 3 study.

*European Multidisciplinary Cancer Congress (ECCO-ESMO)*; September 23–27, 2011; Stockholm, Sweden.

Wang P, **Song X**, Zhao Z, Barber B, **Long S**. Trend of metastasectomy and chemo- and biologic therapy in patients with metastatic colorectal cancer.

*ECCO 15 and 34th ESMO Multidisciplinary Congress*; September 20–24, 2009; Berlin, Germany.

*ISPOR 12th Annual European Congress*; October 24–27, 2009; Paris, France.

Wasif Saif M, **Shi N**, Zelt S. A claims database analysis of capecitabine treatment patterns in patients with gastroesophageal cancer (GEC).

*2008 Gastrointestinal Cancers Symposium*; January 25–27, 2008; Orlando, FL.

Wasif Saif M, **Schulman KL**, Wei W, Saab T. Cost of chemotherapy for patients with metastatic gastroesophageal cancer treated with capecitabine or 5-fluorouracil monotherapy.

*2009 Gastrointestinal Cancers Symposium*; January 15–17, 2009; San Francisco, CA.



Wasif Saif M, **Schulman KL**, Zelt S. Capecitabine in patients with gastroesophageal cancer (GEC): A claims database analysis of adverse events.

*2008 Gastrointestinal Cancers Symposium*; January 25–27, 2008; Orlando, FL.

## Respiratory

---

**Carls GS, Lenhart G, Ozminkowski RJ, Wang S, Coffey R**, McNeil D. A systematic review of the potential cost savings of asthma disease management programs.

*Academy Health Annual Conference*; June 3–5, 2007; Orlando, FL.

**Chang S, Long S**, Leahy M, Crown WH. Healthcare expenditures of patients with comorbid allergic rhinitis and asthma.

*ISPOR 9<sup>th</sup> Annual International Meeting*; May 16–19, 2004; Arlington, VA.

**Durden E, Cao Z**, Curtice T, Zou K, Marfatia A, Shah H. Long-acting bronchodilator treatment type and chronic obstructive pulmonary disease-related inpatient admission among patients with chronic obstructive pulmonary disease in a commercially-insured population.

*CHEST 2009, American College of Chest Physicians*; October 31–November 5, 2009; San Diego, CA.

**Durden E, Cao Z**, Curtice T, Zou KH, Marfatia A, Shah H. Long-acting bronchodilator treatment type and COPD-related medical costs in a commercially-insured population.

*AMCP Educational Symposium*; Oct 7–10, 2009; San Antonio, TX.

**Durden E**, Fairchild C, **Cao Z**. A comparison of therapeutic approaches to allergic rhinitis (AR).

*American College of Allergy, Asthma, and Immunology Annual Meeting*; November 6–8, 2008; Seattle, WA.

**Hawkins K, Baser O**, Phillips AL, Marton JP, Shah H. The burden of chronic obstructive pulmonary disease (COPD) following a medical encounter in a Medicaid population.

*AMCP 17<sup>th</sup> Annual Meeting & Showcase*; April 20–23, 2005; Denver, CO.

**Hawkins K**, Stanford R, **Orsini LM, Ozminkowski RJ, Chang J**. Pharmacotherapy and healthcare expenditures for the treatment of asthma in the Medicaid population.

*ISPOR 9<sup>th</sup> Annual International Meeting*; May 16–19, 2004; Arlington, VA.

**Hawkins K**, Stanford RY, **Orsini LS, Ozminkowski RJ**, Jiang C. Racial differences in pharmacotherapy and healthcare expenditures for the treatment of asthma in a Medicaid population.

*ISPOR 9<sup>th</sup> Annual International Meeting*; May 16–19, 2004; Arlington, VA.

**Mucha L**. Meta-analysis of the effect of smoking intensity on disease morbidity.

*Society for Research on Nicotine and Tobacco 12<sup>th</sup> Annual Meeting*; February 15–18, 2006; Orlando, FL.



**Mucha L**, Seal B, **Lenhart G**, Asche C. Direct and incremental costs of acute respiratory infections by initiating antibiotic.

*ISPOR 12th Annual International Meeting*; May 19–23, 2007; Arlington, VA.

**Ozminkowski RJ**. Health care costs for elderly Medicaid patients treated with nebulized levalbuterol (LEV) or racemic albuterol (RAC).

*American Thoracic Society International Conference*; May 25, 2005; San Diego, CA.

**Ozminkowski RJ, Gust C, Azzolini J, Fox K**. Precursors to asthma.

*6<sup>th</sup> Annual Disease Management Leadership Forum*; October 20–23, 2004; Orlando, FL.

**Palmer L**, Hall C, Katkin J, **Shi N**, Masaquel A, McLaurin K, Mahadevia P. Increased medical costs and use over a year following respiratory syncytial virus lower respiratory tract infection (RSV LRI) among commercially insured late-preterm infants.

*American Academy of Pediatrics National Conference and Exhibition*; October 17–20, 2009; Washington, DC.

**Palmer L**, Hall C, Katkin J, **Shi N**, P Masaquel A, McLaurin K, Mahadevia K. Medical costs and use over a year following respiratory syncytial virus lower respiratory tract infection (RSV LRI) among Medicaid-insured late preterm infants.

*The Pediatric Academic Societies*; May 2–5, 2009; Baltimore, MD.

**Song X**, Costa L, Anderson J, Shenolikar R. The impact of asthma on employee work absenteeism and medical costs.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL.

**Song X**, Shenolikar R, Costa LA, **Anderson J, Chu BC**. The impact of asthma on healthcare utilization and expenditure of pediatric patients.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA. **(Best Poster Finalist)**

## Schizophrenia and Bipolar

.....

**Bonafede M**, Locklear JC, Wahlqvist P, Liberty Fajutrao L, Szamosi J, **Pan K**, Eriksson H. The impact of once-daily extended-release quetiapine fumarate (quetiapine XR) on length of hospitalisation of patients with acute bipolar mania.

*ISPOR 14th Annual European Congress*; November 5–8, 2011; Madrid, Spain.

Centorrino F, **Mark T**, Talamo A, Oh K, Chang J. A comparison of the prevalence of metabolic conditions among bipolar patients vs. general population: An analysis of employer-based health insurance data.

*International Review of Bipolar Disorders*; May 3–5, 2007; Rome, Italy.

Centorrino F, **Mark T**, Talamo A, Oh K, Chang J. The economic burden of metabolic conditions among bipolar patients: An analysis of employer-based health insurance data.

*International Review of Bipolar Disorders*; May 3–5, 2007; Rome, Italy.



Citrome L, Reist C, **Palmer L, Montejano L**, Cuffel B, Harnett J. Impact of ziprasidone dosing on treatment discontinuation rates in subjects with schizophrenia or bipolar disorder.

*American Psychiatric Association, 161st Annual Meeting; May 3–8, 2008; Washington, DC.*

**Durden E**, Choi J, Muser E, **Bagalman E**, Macfadden W, Haskins JT, Dirani R. Healthcare utilization and costs in a commercial population of patients with type I bipolar disorder who relapse frequently.

*American Psychiatric Association Meeting; May 22–26, 2010; New Orleans, LA.*

**Durden E**, Crivera C, Yu-Isenberg KS, **Bagalman E**, Haskins JT, Ascher S, Macfadden W, Dirani R. Health care utilization and expenditures in a large Medicaid population of bipolar disorder patients who relapse frequently.

*2009 U.S. Psychiatric & Mental Health Congress; November 2–5, 2009; Las Vegas, NV.*

**Durden E**, Muser E, Choi J, **Bagalman E**, Dirani R. Psychiatric-related healthcare costs and risk of hospitalization among Medicaid patients with type I bipolar disorder who relapse frequently.

*ISPOR 15th Annual International Meeting; May 15–19, 2010; Atlanta, GA.*

**Marder WD, Stranges E, Houchens B, Coffey R, Wang SS, Schabert L, Kassed C, Mark T.** Using treemaps to assess physical comorbidity risk in patients with bipolar disorder.

*ISPOR 12th Annual European Congress; October 24–27, 2009; Paris, France.*

**Mark TL**, Centorrino F, Talamo A, Oh K, Chang J. The prevalence and costs of metabolic conditions among patients with bipolar disorders as compared to matched controls.

*24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 17–20, 2008; Copenhagen, Denmark*

**Mark T**, Centorrino F, Talamo A, Oh K, Chang J. The prevalence and costs of metabolic conditions among patients with bipolar disorders as compared to matched controls.

*ISPOR 13th Annual International Meeting; May 3–7, 2008; Toronto, Canada.*

Mychaskiw M, Sanders K, Alvir J, **Montejano L, Lenhart G**, O’Gorman C. Association between antipsychotic treatment and clinical and economic outcomes in bipolar disorder.

*American Psychiatric Association Institute on Psychiatric Services; October 8–11, 2009; New York, NY.*

Mychaskiw M, Sanders K, Alvir J, **Montejano L, Lenhart G**, O’Gorman C. Association between choice of antipsychotic treatment and subsequent costs of medical care in patients with bipolar disorder.

*ISPOR 14th Annual International Meeting; May 16–20, 2009; Orlando, FL.*

Panish J, Dirani R, **Mark T, Montejano LB**, Starr HL, Mao L. A schizophrenia or bipolar type I disorder registry: Lessons learned from conducting a registry study with safety net providers.

*ISPOR 16th Annual International Meeting; May 21–25, 2011; Baltimore, MD.*

Reist C, **Mucha LM, Montejano L**, Nguyen H, Cuffel B, Loebel A. Dose trends for atypical antipsychotic treatment of schizophrenia and bipolar disorder.

*2007 Annual Meeting, American Psychiatric Association; May 19–24, 2007; San Diego, CA.*



Reist C, **Mucha LM, Montejano L**, Nguyen H, Cuffel B, Loebel A. Predictors of high-dose ziprasidone use in routine clinical practice.

*2007 Annual Meeting, American Psychiatric Association; May 19–24, 2007; San Diego, CA.*

Reist C, **Mucha LM, Montejano L**, Nguyen H, Harnett J, Garcia M, Loebel A. Dose trends for atypical antipsychotic treatment of schizophrenia and bipolar disorder.

*47th New Clinical Drug Evaluation Unit Annual Conference; June 11–14, 2007; Boca Raton, FL.*

Reist C, **Mucha LM, Montejano L**, Nguyen H, Harnett J, Loebel A. Treatment of schizophrenia and bipolar disorder.

*Seventh International Conference on Bipolar Disorder; June 7–9, 2007; Pittsburgh, PA.*

Sanders K, Mychaskiw M, Alvir J, **Lenhart G, Palmer L**, O’Gorman C. Antipsychotic treatment choice and associated costs of medical care in patients with schizophrenia.

*ISPOR 14th Annual International Meeting; May 16–20, 2009; Orlando, FL.*

Sanders K, Mychaskiw M, Alvir J, **Lenhart G, Palmer L**, O’Gorman C. Association between antipsychotic treatment and clinical and economic outcomes in schizophrenia.

*American Psychiatric Association Institute on Psychiatric Services; October 8–11, 2009; New York, NY.*

Sanders K, **Palmer L, Montejano L, Lenhart G**, Harnett J. Evaluation of psychiatric hospitalizations and expenditures for atypical antipsychotics in a Medicaid cohort with schizophrenia.

*American Psychiatric Association, 161st Annual Meeting; May 3–8, 2008; Washington, DC.*

## Substance Abuse

---

Gastfriend DR, Kranzler HR, **Montejano L, Mark T**, Chalk M. Characteristics, persistence and outcomes of insured patients treated with extended-release naltrexone (XR-NTX) or oral medications

*American Psychiatric Association Meeting; May 22–26, 2010; New Orleans, LA.*

Gastfriend DR, Stephenson JJ, **Montejano L, Wang S**, Kranzler HR. Persistence with oral naltrexone for alcohol treatment: Implications for healthcare utilization.

*2008 Addiction Health Services Research (AHSR) Conference; October 20–22, 2008; Boston, MA.*

Haddox JD, **Palmer L**. Impact of modified-release versus other opioid formulations on health outcomes during episodes of opioid treatment in patients with alcohol-related disorders.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting; August 16–19, 2009; Providence, RI.*



Kranzler HR, **Wang S, Montejano L**. Predictors of adherence to oral naltrexone treatment in an insured U.S. population.

*30th Annual Scientific Meeting of the Research Society on Alcoholism*; July 7–12, 2007; Chicago, IL.

**Mark T**. Substance abuse medication: Trends and prescribing patterns by physician specialty.

*American Public Health Association 135th Annual Meeting & Exposition*; November 3–7, 2007; Washington, DC.

**Mark T, Gastfriend DR, Kranzler HR, Chalk M, Montejano L**. Characteristics and cost outcomes of insured patients treated with extended-release naltrexone or oral alcohol dependence medications.

*AcademyHealth Annual Research Meeting*; June 27–29, 2010; Boston, MA.

**Mark TL, Gastfriend DR, Kranzler HR, Chalk M, Montejano L**. Characteristics and cost outcomes of insured patients treated with extended-release naltrexone (XR-NTX) or oral alcohol dependence medications.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA.

**Mark TL, Kassed CA, Vandivort-Warren R**. Medications for treating substance abuse: Physician prescribing patterns and their implications.

*AcademyHealth Annual Research Meeting*; June 8–10, 2008; Washington, DC.

*Research Society on Alcoholism*; July 2, 2008; Washington DC.

**Mark TL, Montejano L, Kranzler HR, Gastfriend DR, Chalk M**. Characteristics and outcomes of insured patients treated with extended-release naltrexone (XR-NTX) or oral alcohol dependence medications.

*Addiction Health Services Research (AHSR) 2009 Conference*; October 28–30, 2009; San Francisco, CA.

Smith MY, Haddox JD, **Palmer L**. A comparison of health outcomes and healthcare utilization during episodes of modified-release opioid analgesic therapy with and without evidence of an alcohol-related disorder.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting*; August 16–19, 2009; Providence, RI.

Smith M, Haddox JD, **Palmer L, Margolis J**. Alcohol use disorders among chronic pain patients prescribed oral opioid analgesics.

*26th Annual Scientific Meeting, American Pain Society*; May 5–7, 2007; Washington, DC.

Smith M, **Palmer L, Margolis J**. Prevalence and costs of concomitant use of alcohol in Medicaid patients dispensed opioid analgesics for chronic pain.

*23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*; August 19–22, 2007; Quebec City, Canada.

**Stephenson JJ, Montejano L, Wang S, Sikirica M, Kranzler H**. Health care costs associated with pharmacotherapy for alcohol-use disorders in an insured population in the United States.

*AMCP 2006 Educational Conference Hyatt Regency*; October 4–7, 2006; Chicago, IL.



**Stephenson JJ, Montejano L, Wang S**, Sikirica M, Kranzler H. Predictors of oral naltrexone adherence in an insured population in the USA.

*American Academy of Addiction Psychiatry, 17<sup>th</sup> Annual Meeting and Symposium; December 7–10, 2006; St. Petersburg Beach, FL.*

## Women's Health

---

**Bonafede M, Shi N**, Viswanathan HN, Yurgin N. Osteoporosis-related fracture costs among female commercially insured and Medicare patients. **(Best Poster Finalist)**

*ISPOR 16th Annual International Meeting; May 21–25, 2011; Baltimore, MD.*

**Carls G**, Lee DW, **Ozminkowski RJ, Gibson TB, Wang S**, Stewart EA. What does surgical treatment for uterine fibroids really cost?

*55th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists; May 5–9, 2007; San Diego, CA.*

Coyle PK, **Curkendall S, Johnson BH**, Preblick R, Pocoski J, Patel P, Suarez-Zambrano G. Prevalence of pregnancy in multiple sclerosis.

*63rd Annual Meeting of the American Academy of Neurology; April 9–16, 2011; Honolulu, HI.*

Curtis J, Amonkar MM, **Mucha L**, Barr CE, Saag K. Adherence to bisphosphonate therapy results in reduced osteoporosis-related healthcare utilization.

*American Society of Bone and Mineral Research 28th Annual Meeting; September 15–19, 2006; Philadelphia, PA.*

*70<sup>th</sup> Annual Meeting of the American College of Rheumatology; November 10–15, 2006; Washington DC.*

Curtis J, Amonkar MM, **Mucha L**, Barr CE, Saag K. Osteoporotic women adherent to bisphosphonate therapy have reduced osteoporosis-related and total healthcare costs.

*American Society of Bone and Mineral Research 28th Annual Meeting; September 15–19, 2006; Philadelphia, PA.*

*70<sup>th</sup> Annual Meeting of the American College of Rheumatology; November 10–15, 2006; Washington DC.*

**Foley K**, Foley D, **Johnson BH**, Shah H. Drivers of healthcare costs in women with hypoactive sexual desire disorder (HSDD).

*ISPOR 14th Annual International Meeting; May 16–20, 2009; Orlando, FL.*

**Foley K**, Foley D, **Johnson BH**, Shah H. Healthcare utilization and costs among women with female sexual dysfunction (FSD) and hypoactive sexual desire disorder (HSDD).

*ISPOR 14th Annual International Meeting; May 16–20, 2009; Orlando, FL.*



**Foley K, Foley D, Johnson B, Shah H.** Treatment patterns of women diagnosed with HSDD or other forms of FSD in the primary care and ob-gyn setting.

*12th Annual NPWH Premier Women's Healthcare Conference; October 14–17, 2009; Providence, RI.*

**Foley K, Foley D, Johnson BH, Shah H.** Treatment of hypoactive sexual desire disorder (HSDD) for women with and without comorbid conditions.

*American Society for Reproductive Medicine Annual Meeting; October 17–21, 2009; Atlanta, GA.*

Foster SA, **Curkendall S, Shi N, Stock J, Chu B, Burge R, Diakun D, Krege JH.** Fractures in commercial and Medicare patients treated with raloxifene or alendronate: A retrospective database analysis.

*American Society for Bone and Mineral Research Annual Meeting; October 15–19, 2010; Toronto, Canada.*

Foster S, **Foley K, Baser O, Meadows E, Long S.** Trends in the clinical management of fragile fracture before and after the new HEDIS osteoporosis management measures in a Medicare population.

*ISPOR 11<sup>th</sup> Annual International Meeting; May 20–24, 2006; Philadelphia, PA.*

Foster SA, **Foley KA, Meadows ES, Johnston JA, Wang S, Pohl GM, Long SR.** Adherence and persistence with teriparatide therapy in commercial insurance plans and managed Medicare.

*American Society for Bone and Mineral Research (ASBMR) Annual Meeting; September 16–19, 2007; Honolulu, HI.*

Foster S, **Foley KA, Meadows ES, Johnston JA, Wang S, Pohl GM, Long SR.** Characteristics of patients initiating teriparatide therapy.

*AMCP 2006 Educational Conference Hyatt Regency; October 4–7, 2006; Chicago, IL.*

**Johnson BH, Foley KA, Foley DT, Shah H.** Diagnosis and treatment of female sexual dysfunction/hypoactive sexual desire disorder by OB/GYNs.

*American College of Obstetricians and Gynecologists 57th Annual Clinical Meeting; May 2–6, 2009; Chicago, IL.*

**Johnson BH, Palmer L, Foley D.** Billing patterns for the treatment of hypoactive sexual desire disorder.

*ISPOR 15th Annual International Meeting; May 15–19, 2010; Atlanta, GA.*

**Johnson BH, Palmer L, Foley D.** Diagnosis and treatment of women with hypoactive sexual desire disorder and depression/anxiety.

*ISPOR 15th Annual International Meeting; May 15–19, 2010; Atlanta, GA.*

**Johnston SS, O'Malley CD, Palmer LA, Chu BC, Richardson LC.** Fractures in breast cancer patients treated with hormonal therapies: A retrospective cohort study.

*3rd North American Congress of Epidemiology; June 21–24, 2011; Montreal, Canada.*

Kinchen K, **Chang S, Girts TK, Long S, Pantos B.** The direct costs of stress urinary incontinence treatment among women in a Medicaid population.

*ISPOR 10<sup>th</sup> Annual International Meeting; May 15–18, 2005; Washington, DC.*



Lee DW, **Carls G, Ozminkowski RJ, Gibson TB, Wang S**, Stewart EA. Incidence, prevalence, and treatment for uterine fibroids in insured women.

*55th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists*; May 5–9, 2007; San Diego, CA.

Lee DW, **Ozminkowski RJ, Carls GS, Wang S, Gibson TB**, Stewart EA. The direct and indirect cost burden of treated uterine fibroids.

*ISPOR 12th Annual International Meeting*; May 19–23, 2007; Arlington, VA.

*Academy Health Annual Conference*; June 3–5, 2007; Orlando, FL.

**Orsini LS, Long S**, Pantos B, **Wang S**, Rousculp M. Healthcare utilization and expenditures: A study of severe osteoporosis.

*ISPOR 9<sup>th</sup> Annual International Meeting*; May 16–19, 2004; Arlington, VA.

**Palmer L, Johnson BH**, Foley D. Healthcare utilization and costs for the treatment of hypoactive sexual desire disorder.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA.

Schnitzer T, **Stephenson J, Long S, Abbott T**, Sen S, Chen Y. Systematic review of ibandronate for postmenopausal osteoporosis.

*ISPOR 8<sup>th</sup> Annual European Congress*; November 6–8, 2005; Florence, Italy.

**Song X**, Waters HC, Pan K, Subramaniam D, **Sedgley R**, Raff GJ. Laparoscopic supracervical hysterectomy versus laparoscopic-assisted vaginal hysterectomy: Post-surgical outcomes and costs.

*ISPOR 16th Annual International Meeting*; May 21–25, 2011; Baltimore, MD.

Stewart EA, Lee DW, **Carls GS, Ozminkowski RJ, Gibson TB, Wang S**. Surgical treatment for uterine fibroids: Adverse events, and 1-year retreatment rates.

*55th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists*; May 5–9, 2007; San Diego, CA.

## Research Methodology

---

**Baser O**. An application of latent class cluster analysis in outcomes research: Identifying high-cost insomnia patients.

*Academy Health Annual Conference*; June 3–5, 2007; Orlando, FL.

**Baser O**. A method to remove continuous enrollment requirement from pharmacoecoeconomical studies.

*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.

**Baser O**. A test to determine possible selection bias due to censoring in medical cost estimation.

*25<sup>th</sup> Annual Meeting of the American Economic Association*; January 7–9, 2005; Philadelphia, PA.



- Baser O.** Choosing among different types of matching techniques.  
*ISPOR 10<sup>th</sup> Annual International Meeting*; May 15–18, 2005; Washington, DC.
- Baser O.** Continuous enrollment requirement: Do we really need it?  
*Inaugural Conference of the American Society of Health Economists*; June 4–7, 2006; Madison, WI.
- Baser O.** Controlling selection bias on continuous variables.  
*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.
- Baser O.** Estimation of censored medical count data.  
*ISPOR 10<sup>th</sup> Annual International Meeting*; May 15–18, 2005; Washington, DC.
- Baser O.** Estimation power of different comorbidity indexes.  
*AcademyHealth Annual Research Meeting*; June 25–27, 2006; Washington, DC.
- Baser O.** Failure of regression adjustment against propensity score matching.  
*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.
- Baser O.** One solution to three problems.  
*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.
- Baser O.** Performance of bootstrapping in discrete choice models.  
*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.
- Baser O.** Propensity score matching and multivariate analysis: Complement or substitute?  
*AMCP 18<sup>th</sup> Annual Meeting & Showcase*; April 5–8, 2006; Seattle, WA.
- Baser O.** Propensity score matching with more than two categories.  
*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.
- Baser O.** Propensity score modeling with limited overlap.  
*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.
- Baser O.** Propensity score matching with more than two categories.  
*AcademyHealth Annual Research Meeting*; June 25–27, 2006; Washington, DC.
- Baser O.** Retransformation of estimated log-transformed costs when the errors present heteroskedasticity.  
*ISPOR 10<sup>th</sup> Annual International Meeting*; May 15–18, 2005; Washington, DC.
- Baser O.** The performance of bootstrapping in discrete choice models.  
*AcademyHealth Annual Research Meeting*; June 25–27, 2006; Washington, DC.
- Baser O.** Too much ado about propensity score matching?  
*6<sup>th</sup> International Conference on Health Policy Research*; October 28–30, 2005; Boston, MA.



**Baser O.** Using propensity score matching techniques for average treatment effect: Application to triptan use.

*Academy Health Annual Conference; June 3–5, 2007; Orlando, FL.*

**Baser O, Bradley C, Gardnier J, Given C.** Testing and correcting for non-random selection bias due to censoring: An application to medical cost.

*ISPOR 9<sup>th</sup> Annual International Meeting; May 16–19, 2004; Arlington, VA.*

**Baser O, Crown WH.** Choosing among different types of bootstrapping methods.

*ISPOR 9<sup>th</sup> Annual International Meeting; May 16–19, 2004; Arlington, VA.*

**Baser O, Gardiner J, Bradley C, Given C.** Censored medical cost estimation.

*ISPOR 9<sup>th</sup> Annual International Meeting; May 16–19, 2004; Arlington, VA.*

**Baser O, Given C.** To weight or not to weight.

*ISPOR 9<sup>th</sup> Annual International Meeting; May 16–19, 2004; Arlington, VA.*

**Baser O, Long S.** Which one is logical? Logit or rare event logit (re-logit).

*ISPOR 10<sup>th</sup> Annual International Meeting; May 15–18, 2005; Washington, DC.*

**Baser O, Stephenson J.** The estimation power of alternative comorbidity indexes.

*ISPOR 11<sup>th</sup> Annual International Meeting; May 20–24, 2006; Philadelphia, PA.*

**Chang S, Hansen LG, Marder WD.** A methodology for projecting disease prevalence, treatment and expenditures for the US employer-insured population.

*International Society of Pharmacoeconomics and Outcomes Research, May 20, 2007; Arlington, VA.*

**Chu E, Wei W, Schulman KL.** Selection bias and propensity score matching in a claims database analysis of the frequency and cost of chemotherapy-related complications.

*AMCP 2008 Educational Meeting; October 15–18, 2008; Kansas City, MO.*

**Curkendall S, Liang H, Gardarsdottir H, Misra A.** Coding algorithms for defining study population in database studies: A literature review.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting; August 14–17, 2011; Chicago, IL.*

**Curkendall S, Mark M, Liang H, Gardarsdottir H.** Influence of selection criteria on cohort characteristics.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting; August 19–22, 2010; Brighton, UK.*

**Foley K, Chang S, Misra A, Hansen L.** Monitoring potential drug-drug interactions: An application for prescription claims databases.

*ISPOR Annual European Congress; November 8–11, 2008; Athens, Greece.*



**Gagnon DD.** Estimating the confidence interval for the cost-effectiveness ratio from a family of regressions on net monetary benefit. **(Best Poster Finalist)**

*ISPOR 14th Annual European Congress*; November 5–8, 2011; Madrid, Spain.

**Gibson TB, Jing Y, Bagalman JE, Kim E, Burton WN, Carls GS, Tran QV, Pikalov A, Goetzel RZ.** Identification of treatment resistant depression in claims data: A comparison of methods. **(Best Poster Finalist)**

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL.

**Hansen L, Chang, S, Foley K.** Prevalence of conditions in the U.S. employer insured population: A methodology for projecting from a convenience sample.

*ISPOR Annual European Congress*; October 20–23, 2007; Dublin, Ireland.

**Juneau P, Huse DM.** Model and covariate visualization aids for enhancing the interpretation of steps in the high dimensional propensity scoring adjustment procedure.

*ISPOR 14th Annual European Congress*; November 5–8, 2011; Madrid, Spain.

**Ozminkowski RJ.** Using medical claims data and clinical literature to forecast the impact of adding a new drug onto the formulary: A case study of insomnia treatment.

*19<sup>th</sup> Annual Meeting of the Associated Professional Sleep Societies*; June 18–23, 2005; Denver, CO.

**Ozminkowski RJ, Goetzel RZ.** Estimating changes in health risk and medical expenditures for the Dow Chemical Company, Motorola and Union Pacific Railroad—An innovative method for projection ROI.

*National Prevention Summit*; October 26–27, 2004; Washington, DC.

**Ozminkowski RJ, Goetzel RZ, Chang S, Long S, Lerner D.** The application of two health and productivity instruments at a large employer.

*ISPOR 9<sup>th</sup> Annual International Meeting*; May 16–19 2004; Arlington, VA.

**Ozminkowski RJ, Lenhart G, Wang S, et al.** Forecasting the impact of adding new drug on formulary using medical claims data and clinical literature: A case study for insomnia treatment.

*ISPOR 10<sup>th</sup> Annual International Meeting*; May 15–18, 2005; Washington, DC.

**Ozminkowski RJ, Lenhart G, Wang S, et al.** Using medical claims data and clinical literature to forecast the impact of adding a new drug onto the formulary: A case study of insomnia treatment.

*AMCP 17<sup>th</sup> Annual Meeting & Showcase*; April 20–23, 2005; Denver, CO.

Roebuck MC, **Gibson TB.** Measurement and modeling issues with adherence to pharmacotherapy.

*ACMP Educational Meeting*; October 13–16, 2010; St. Louis, MO.

**Song X, Long SR, Marder WD, Sullivan SD, Kallich J.** The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.

*50th ASH (American Society of Hematology) Annual Meeting and Exposition*; December 6–9, 2008; San Francisco, CA.



**Zhun C, Durden E.** Comparison of propensity score matching and use of inverse probability of treatment weights.

*ISPOR 14th Annual International Meeting*; May 16–20, 2009; Orlando, FL.

## Other

---

**Baser O.** Is the cure worse than the disease?

*ISPOR 12th Annual International Meeting*; May 19–23, 2007; Arlington, VA.

**Cao Z, Margolis J, Mark T.** Comparison of difference-in-difference and propensity score methods in regressions with binary outcome.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA.

**Cao Z, Song X, Mark T.** Estimating time-profiled economic burden of illness.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA.

Chernew M, **Gibson T.** Cost sharing and health system performance.

*American Economic Association/Annual Meeting of the Allied Social Science Associations*; January 4, 2008; New Orleans, LA.

**Curkendall S, Hansen L, Chang S, Mark T.** Projected exposure to drugs on FDA's watch list.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting*; August 16–19, 2009; Providence, RI.

Danielson E, **Chang S, Long S.** Linking claims and electronic medical record (EMR) data for a hypertension study.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA.

Ellis L, Bailey RA, Forlenza J, Senbetta M, **Landsman-Blumberg P.** Transfusion and post hospital discharge outcomes in elective total hip replacement (THR) or total knee replacement (TKR) surgery among adults <65 years of age.

*52nd ASH Annual Meeting and Exposition*; December 4–7, 2010; Orlando, FL.

**Foley K.** Internet education tool associated with greater treatment awareness and communication.

*8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke*; May 9–11, 2007; Washington, DC.

**Foley K, Hansen L.** Understanding patient beliefs to design medication adherence messaging.

*ISPOR 11<sup>th</sup> Annual International Meeting*; May 20–24, 2006; Philadelphia, PA.

**Foley K, Hansen L.** Using patient-focused research to design effective messages and delivery channels for adherence interventions.

*AcademyHealth Annual Research Meeting*; June 25–27, 2006; Washington, DC.



**Foley K, Lim S, Schulman KL.** Methodological considerations in modeling the economic value of diagnostic accuracy.

*ISPOR 16th Annual International Meeting; May 21–25, 2011; Baltimore, MD.*

**Foley K, Shi N, Lenhart G, Badamgarav E.** Costs associated with non-hip, non-vertebral (NHNV) fractures in a managed care setting.

*The American Society for Bone and Mineral Research (ASBMR) 30th Annual Meeting; September 12–16, 2008; Montreal, Quebec, Canada.*

**Foley K, Shi N, Lenhart G, Badamgarav E.** Direct medical costs associated with the treatment of non-hip, non-vertebral (NHNV), hip, and vertebral fractures in a managed care setting.

*The American Society for Bone and Mineral Research (ASBMR) 30th Annual Meeting; September 12–16, 2008; Montreal, Quebec, Canada.*

**Foster D, Young J, Heller S.** A risk-adjusted, all-payer, 30-day readmission methodology.

*AcademyHealth Annual Research Meeting; June 27–29, 2010; Boston, MA.*

**Galantowicz S, Flint J, Larson S.** Obtaining participant feedback on home and community based services quality.

*AcademyHealth Annual Research Meeting; June 27–29, 2010; Boston, MA.*

Gerson L, **Bonafede M, Princic N, Gregory C, Farr A, Balu S.** Development of a claims-based algorithm for refractory GERD.

*Digestive Disease Week; May 7–10, 2011; Chicago, IL.*

Gerson LB, **Bonafede M, Princic N, Gregory C, Farr A, Chu BC, Balu S.** The economic burden of refractory GERD: A retrospective claims database study.

*ISPOR 16th Annual International Meeting; May 21–25, 2011; Baltimore, MD.*

**Gibson T.** Prescription drug cost-sharing among commercially insured children and adults with chronic illness.

*ISPOR 12th Annual International Meeting; May 19–23, 2007; Arlington, VA.*

*Academy Health Annual Conference; June 3–5, 2007; Orlando, FL.*

**Gibson TB, Batata A, Chernew ME.** Geographic variation in medication adherence.

*ISPOR 14th Annual International Meeting; May 16–20, 2009; Orlando, FL.*

**Gibson TB, Owens PJ, Barrett M, Zodet MW, Machlin SR, Nisbet J, Mell AG, Weinick RM.** Comparison of emergency department visit data sources.

*American Public Health Association 136th Annual Meeting; October 25–29, 2008; San Diego, CA.*

**Gibson TB, Waddell JL, Vogtmann EJ, Williams TV, Hidalgo J.** A qualitative analysis of TRICARE retiree beneficiary decision-making—Lessons for other payers.

*AcademyHealth Annual Research Meeting; June 27–29, 2010; Boston, MA.*



**Gibson TB, Waddell JL, Vogtmann EJ, Williams TV, Hidalgo J.** Retiree benefits: An examination of employer-sponsored benefit offerings and the effects on out-of-pocket spending.

*AcademyHealth Annual Research Meeting; June 27–29, 2010; Boston, MA.*

**Hansen L, Chang S, Foley K.** Prevalence of conditions in the US employer-insured population.

*ISPOR 13th Annual International Meeting; May 3–7, 2008; Toronto, Canada.*

**Hansen L, Foley K.** Using research on patients' beliefs to inform messaging and delivery channels for medication adherence improvement.

*PMSA Annual Conference; April 29–May 2, 2007; Fort Lauderdale, FL.*

**Huse D, Curkendall S.** Linking person-level inpatient data to longitudinal records.

*ISPOR 12th Annual European Congress; October 24–27, 2009; Paris, France.*

**Huse D, Lenhart G.** Use of self-reported health status to predict employee medical expenditures.

*ISPOR 12th Annual European Congress; October 24–27, 2009; Paris, France.*

**Huse D, Marder W, Hansen L.** Impact of Vioxx withdrawal on volume of total hip and knee replacements.

*ISPOR Annual European Congress; November 8–11, 2008; Athens, Greece.*

**Huse D, Marder W, Hansen L.** What happened to Vioxx users?

*ISPOR 13th Annual International Meeting; May 3–7, 2008; Toronto, Canada.*

**Landsman-Blumberg P, Wei W, Douglas D, Smith D, Camargo C.** A retrospective database study of characteristics of US adults seen in the emergency department or hospital with food-induced anaphylaxis.

*American College of Allergy, Asthma, and Immunology (ACAAI's) 2011 Annual Meeting; November 3–8, 2011; Boston, MA.*

**Landsman-Blumberg P, Wei W, Douglas D, Smith D, Camargo C.** A retrospective database study of concordance with recommended post-discharge anaphylaxis care among US adults seen in the emergency department or hospital with food-induced anaphylaxis.

*American College of Allergy, Asthma, and Immunology (ACAAI's) 2011 Annual Meeting; November 3–8, 2011; Boston, MA.*

**Long S, Misra A.** Application of Pareto's Principle to understand cost drivers in healthcare.

*ISPOR 13<sup>th</sup> Annual European Congress; November 6–9, 2010; Prague, Czech Republic.*

Mansley EC, **Mark TL, Teutsch SM.** Differences in price sensitivity for 15 types of chronic disease medications: Evidence of differences in perceived necessity?

*ISPOR 14th Annual International Meeting; May 16–20, 2009; Orlando, FL.*

**Marder WD, Chang S, Pepitone T, Hatzmann M, Mark T, Goodrich K.** US government initiatives for supporting comparative effectiveness research: An example from Project Libra.

*ISPOR 14th Annual European Congress; November 5–8, 2011; Madrid, Spain.*



**Margolis J, Johnson B, Fowler R, Mody-Patel N, Malhotra M.** Differing treatment patterns between commercially insured and Medicaid MS patients.

*23rd CMSC Annual Meeting; May 27–30, 2009; Atlanta, GA.*

*134th Annual Meeting of the American Neurological Association; October 11–14, 2009; Baltimore, MD.*

**Mark T.** The impact of comparative effectiveness information on prescribing patterns: A case study.

*International Society for Pharmacoepidemiology (ISPE) Annual Meeting; August 16–19, 2009; Providence, RI.*

**Mark T.** Provider and patient opinions on technology assisted patient reported outcomes.

*Academy Health Annual Conference; June 3–5, 2007; Orlando, FL.*

**Mark T.** Survey and chart review evaluation of the patient assessment, care and educational system.

*32nd Annual Oncology Nursing Society Congress; April 24–27, 2007; Las Vegas, NV.*

**Montejano L, Le TK, Cao Z, Zhao Y, Ang D.** Healthcare costs of newly diagnosed versus existing osteoarthritis patients.

*30th Annual Scientific Meeting of the American Pain Society; May 19–21, 2011; Austin, TX.*

Mopsik J, Goodman C, Brown J, **Mark T**, Love D. The use of administrative claims to support comparative effectiveness research.

*AcademyHealth Annual Research Meeting; June 12–14, 2011; Seattle, WA.*

Morgan SL, **Johnston SS, Lenhart G**, Cherkowski G, **Palmer L**, O'Malley CD. Trends in dual-energy x-ray absorptiometry (DXA) utilization, 2000–2009.

*17th Annual Meeting of the International Society for Clinical Densitometry; April 6–9, 2011; Miami, FL.*

**Orsini LS, Huse DM, Lenhart G.** Utilization, re-treatment rates and cost of 7-day, 10-day and 14-day helicobacter pylori (H. Pylori) treatment regimens: Data from U.S. public and private payers.

*American College of Gastroenterology 69<sup>th</sup> Annual Scientific Meeting; October 29–November 3, 2004; Orlando, FL.*

**Orsini LS, Huse DM, Lenhart G.** Utilization, re-treatment rates and cost of 7-day, 10-day and 14-day helicobacter pylori (H. Pylori) treatment regimens: Insights from a Medicaid analysis.

*American College of Gastroenterology 69<sup>th</sup> Annual Scientific Meeting; October 29–November 3, 2004; Orlando, FL.*

**Orsini LS, Lenhart G**, Flanders S, **Huse D**, Dodd SL, Lomax K. Utilization, re-treatment, and cost of differing lengths of H. pylori treatment regimens from U.S. health care claims databases.

*ISPOR 10<sup>th</sup> Annual International Meeting; May 15–18, 2005; Washington, DC.*

**Ozminkowski RJ, Goetzel RZ, Shechter D**, Stapleton DC, **Baser O**, Lapin PJ. Predictors of preventive services' use among medicare beneficiaries.

*National Prevention Summit; October 26–27, 2004; Washington, DC.*



**Palmer L, Johnston SS**, Rousculp M, Nichol KL, Mahadevia PJ. Evaluation of agreement between Internet-based self- and proxy-reported healthcare utilization and administrative healthcare claims.

*AcademyHealth Annual Research Meeting*; June 27–29, 2010; Boston, MA.

Seal B, **Mucha L, Lenhart G**, Asche C. Incremental costs associated with antibiotics prescribed for acute otitis media.

*ISPOR 12th Annual International Meeting*; May 19–23, 2007; Arlington, VA.

**Shi N, Song X**, Badamgarav E, Kallich J, **Varker H, Lenhart G**, Curtis JR. Cost burden of second fracture in patients with commercial insurance.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA. **(Best Poster Finalist)**

**Song X, Shi N**, Badamgarav E, Kallich J, **Varker H, Lenhart G**, Curtis JR. Cost of second fracture among Medicare patients with initial hip, vertebral, and non-hip non-vertebral (NHNV) fractures.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA.

**Song X, Shi N**, Yurgin N, Oglesby A, Dent R, Bhandari M, Do T. Incremental cost of fracture non-union in patients with tibia fracture and internal fixation surgery.

*26th Annual Meeting of the Orthopaedic Trauma Association*; October 13–16, 2010; Baltimore, MD.

**Stranges E, Russo A**, Friedman B. Procedures with the most rapidly increasing hospital costs.

*ISPOR 15th Annual International Meeting*; May 15–19, 2010; Atlanta, GA.

**Weiss K, Conklin JE**. The Bridges to Excellence Program demonstrates success of physician incentives.

*AcademyHealth Annual Research Meeting*; June 6–8, 2004; San Diego, CA.

To contact Thomson Reuters regarding these and other authored posters, please e-mail [healthcare.pharma@thomsonreuters.com](mailto:healthcare.pharma@thomsonreuters.com).